



PROGRAM

FEBRUARY 26-29
MONTREAL, QC

Celebrate the 20th anniversary of CDDW™!

CDDW™ has gone mobile!

Scan to download



Get the CDDW™ app on your mobile device now, for free.

① Download the Guidebook app.



② Search for “CDDW 2016” or scan the QR code above.

③ Start planning your CDDW™ experience!

guidebook

GENERAL INFORMATION FOR THE 2016 CANADIAN DIGESTIVE DISEASES WEEK™ (CDDW™)

SCIENTIFIC SESSIONS:

The **Gastroenterology Residents in Training (GRIT) Program** (by invitation only) will be held at the Fairmont Queen Elizabeth.

Registration Desk Hours – Foyer, Conference Level

| | |
|------------------------|-------------|
| Tuesday, February 23 | 12h00-21h30 |
| Wednesday, February 24 | 08h00-20h30 |
| Thursday, February 25 | 07h00-17h00 |

The **Scholars' and Research Topics in Gastrointestinal (GI) Disease Programs** (invitation only) will be held at the Fairmont Queen Elizabeth.

Registration Desk Hours – Foyer, Conference Level

| | |
|------------------------|-------------|
| Wednesday, February 24 | 08h00-20h30 |
| Thursday, February 25 | 07h00-17h00 |

All **core sessions of CDDW™** will be held at the Fairmont Queen Elizabeth. Registration Desk hours – **Mezzanine Level**

| | |
|-----------------------|-------------|
| Thursday, February 25 | 17h00-21h00 |
| Friday, February 26 | 07h00-18h30 |
| Saturday, February 27 | 07h00-18h30 |
| Sunday, February 28 | 07h30-18h30 |
| Monday, February 29 | 07h30-14h00 |

EXHIBIT HOURS

The Exhibit and Trade Show will be held in the **Le Grand Salon/Hochelagas 1-3** and will be open as follows:

| | |
|-----------------------|-------------|
| Friday, February 26 | 09h30-18h30 |
| Saturday, February 27 | 10h30-15h30 |
| Sunday, February 28 | 10h30-15h30 |

SPEAKER READY ROOM

Please note that all speakers are asked to present themselves at the Speaker Ready Room, **Saint Charles**, at least two hours before their presentation.

Speaker Ready Room Hours

| | |
|-------------------------------|-------------|
| Thursday, February 25 | 17h00-21h00 |
| Friday-Sunday, February 26-28 | 07h00-18h00 |
| Monday, February 29 | 07h00-14h00 |

NO presentation preparation/loading for plenary sessions will be permitted to take place in rooms Marquette/Jolliett, Duluth or the Mackenzie. Breakfast and small group presentations may be loaded in those rooms.

Centre Ice Gala – Sunday February 28

Pull on your favourite hockey jersey, and enjoy the company of fellow hockey fans as CDDW™ hosts the "Centre Ice Gala". Treat your taste buds to the most exotic stadium cuisine, test out your stick handling skills, and skate the night away with tunes from our own Power Play DJ. Purchase tickets (\$100 + tax) online and also at registration on-site.

CanMEDS ROLES

CanMEDS is a framework that identifies and describes the abilities physicians require to effectively meet the health care needs of the people they serve. These abilities are grouped thematically under seven roles: Medical Expert (the integrating role), Communicator, Collaborator, Leader, Health Advocate, Scholar and Professional. The CDDW™ program will include CanMEDS roles which will be identified at the beginning of each session. For more information on these newly revised definitions, visit:

<http://www.royalcollege.ca/portal/page/portal/rc/canmeds/framework>.

ACCREDITATION

The CDDW™ Meeting is accredited as a group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada (RCPSC) (as the conference overall includes at least 25% interactive time). See page 35 for a listing of credits per session. Financial support for sessions, as indicated within the program, is through educational grants. CDDW™ is in compliance with the CQDPCM (Quebec) Code of Ethics. For more information, please go to: http://www.cemcq.qc.ca/en/index_guide.cfm.

Live educational activities, occurring in Canada, recognized by the RCPSC as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medical Specialists eligible for ECMEC credits.

Through an agreement between the RCPSC and the American Medical Association, physicians may convert RCPSC MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert RCPSC MOC credit to AMA credit can be found at <http://www.amaassn.org/go/internationalcme>

The 2016 CDDW™ is endorsed by:

Faculty who are American College of Gastroenterology Fellows or Masters are identified throughout the program by the * symbol



CDDW™ IMPLEMENTATION COMMITTEE

Co-Chairs

David Armstrong, *CAG President Elect*
Richard Schreiber, *CASL President Elect*

CAG Committee

Derek McKay, *Past Co-Chair*
Kevin Waschke, *Education*
François Boudreau, *Research*
Wallace MacNaughton, *Finance*
Paul Sinclair, *Executive Director*

GRIT Course

Mark Borgonkar, Geoff Williams

CASL Committee

Eberhard Renner, *Past Co-Chair*
Hemant Shah, *Education*
Christopher Rose, *Research*
Kelly Burak, *Finance*

Scholars' Program

Herbert Brill, Saumya Jayakumar

Research Topics in GI Disease

Gilaad Kaplan, Elena Verdu

CDDW™ – PROGRAM AT A GLANCE

| Start | FRIDAY February 26 | | | SATURDAY February 27 | | | | | SUNDAY February 28 | | | | MONDAY February 29 | | Start | | |
|---------|--------------------------------|--------------------------------------|----------------------|--------------------------------|---------------------------------|--|------------------------------------|---|----------------------------------|--------------------------|---|-----------------------|---------------------------------------|---------------------------|--------------------------------|---|--------------|
| 07h00 ▲ | | | | CAG Open Mic | | | | | | | | | | | 07h00 ▲ | | |
| 07h30 ▲ | | | | | | | | | | | | | | | 07h30 ▲ | | |
| 08h00 ▲ | IBD Microbiota | Community-based GI and Liver Disease | | Epigenetics of GI Cancer | Difficult AILD Cases | | Celiac Disease | Barrett's Esophagus | Innate Mucosal Immunology | HRS and SBP | Difficult Cases in CD | H pylori Therapeutics | Difficult Cases in Ulcerative Colitis | | 08h00 ▲ | | |
| 08h30 ▲ | | | | | | CASL Paper Session 1 | | | | | | | | | 08h30 ▲ | | |
| 09h00 ▲ | | | | | | Precision Medicine in Gastroenterology | CASL Paper Session 2 | Luminal Signaling to Nerves in Functional Disorders | | The Future of Hepatology | 2015 Papers Influencing Practice | 09h00 ▲ | | | | | |
| 09h30 ▲ | | | | | Exhibits & Coffee Break | | | | | | | 09h30 ▲ | | | | | |
| 10h00 ▲ | CAG/CCC Student Prizes | Clinical papers | Inpatient Hepatology | CASL-CLF Gold Medal Lecture | | | | | Exhibits & Coffee Break | | | | Coffee Break | 10h00 ▲ | | | |
| 10h30 ▲ | | | | Exhibits & Coffee Break | | | | | Exhibits & Coffee Break | | | | 10h30 ▲ | | | | |
| 11h00 ▲ | | | | Small Group Sessions | | | | | Small Group Sessions | | | | Small Groups | 11h00 ▲ | | | |
| 11h30 ▲ | Exhibits & Lunch (11h30-12h30) | | | Small Group Sessions | | | | | Small Group Sessions | | | | Small Groups | | 11h30 ▲ | | |
| 12h00 ▲ | | | | | | | | | | | | | | | 12h00 ▲ | | |
| 12h30 ▲ | Cellular Reprogramming | Safety Monitoring | | Exhibits & Lunch (12h30-13h30) | | | | | Exhibits & Lunch (12h30-13h30) | | | | Lunch (12h30-13h30) | | 12h30 ▲ | | |
| 13h00 ▲ | | | | Research Career Development | | | | | Updates in Pediatric Cholestasis | | The Role of Nutrition in Gastroenterology | | Research Award Lectures | Hepato-cellular Carcinoma | Rapid Fire 2015 Journal Review | Therapeutics in IBD: Past, present and future | 13h00 ▲ |
| 13h30 ▲ | | | | | | | | | | | | | | | | | 13h30 ▲ |
| 14h00 ▲ | | | | Exhibits & Coffee Break | | | | | | | | | | | | 14h00 ▲ | |
| 14h30 ▲ | | | | | | | | | | | | | 14h30 ▲ | | | | |
| 15h00 ▲ | Colonic Motility | Video Endoscopy | | Exhibits & Coffee Break | | | | | Exhibits & Coffee Break | | | | | | 15h00 ▲ | | |
| 15h30 ▲ | | | | Kopelman Lecture | Optimizing Fatty Liver Outcomes | | Monitoring Disease Activity in IBD | | New Technologies | HCV Update | Diarrhea and Constipation | | | | 15h30 ▲ | | |
| 16h00 ▲ | | | | | | | | | | | | | | | 16h00 ▲ | | |
| 16h30 ▲ | CASL AGM | CAG AGM | | | | | | | | 16h30 ▲ | | | | | | | |
| 17h00 ▲ | | | | McKenna Reception | | | | | Awards Ceremony | | | | | | 17h00 ▲ | | |
| 17h30 ▲ | CDDW™ Opening Reception | | | McKenna Lecture | | | | | | | | | | | 17h30 ▲ | | |
| 18h00 ▲ | | | | | | | | | | | | | | | 18h00 ▲ | | |
| 18h30 ▲ | Trainee Mixer | | | Poster Session 1 | | | | | Poster Session 2 | | | | | | 18h30 ▲ | | |
| 19h00 ▲ | | | | | | | | | | | | | | | 19h00 ▲ | | |
| 19h30 ▲ | | | | | | | | | | | | | | | 19h30 ▲ | | |
| 20h00 ▲ | | | | | | | | | | | | | | | | | Gala Evening |

AGM annual general meeting; AILD autoimmune liver disease; CCC Crohn's and Colitis Canada; CD Crohn's disease; CLF Canadian Liver Foundation; GI gastrointestinal; *H pylori* *Helicobacter pylori*; HCV hepatitis C virus; HRS hepatorenal syndrome; IBD inflammatory bowel disease; SBP spontaneous bacterial peritonitis

OVERALL LEARNING OBJECTIVE FOR CDDW™ 2016

At the end of the conference delegates will be able to:

1. Identify evolving new areas of clinical and basic research in gastroenterology and hepatology.
2. Affirm through evaluation of the evidence that knowledge and management strategies are current.
3. Formulate management strategies for patients with gastrointestinal, including liver, disease.
4. Compare and contrast a wide variety of therapeutic approaches in the care of patients with gastrointestinal, including liver, diseases.
5. Recognize the importance of quality measures and patient safety initiatives in clinical and endoscopic practice.
6. Interact with colleagues to foster a community of practice.

CAG/CASL POSTGRADUATE COURSE

Specialists may be defined by their knowledge of the leading edge issues in gastroenterology and hepatology. The Postgraduate Course is intended to bring you up to date on developments in selected areas and get you ready for the challenges of 2016.

08h00-09h30

**CAG/CASL POSTGRADUATE COURSE:
Community-based Gastrointestinal and Liver Disease**
Marquette/Joliet**Learning Objectives:**

At the end of this session participants will be able to:

1. Review the selection of biologic agents to treat IBD and understand the role of combination therapy.
2. Discuss the time interval of endoscopic surveillance for: IBD-associated neoplasia, colonic polyps, and Barrett's esophagus.
3. Describe the staging of hepatitis C disease, and explore the role of community gastroenterologists in accessing and implementing new treatments.

Co-Chairs: Geoffrey Nguyen, University of Toronto and Kevork Peltekian, Dalhousie University

- Mirror, Mirror on the Wall, Which Biologic Combo Will Fare Best of All?
Brian Bressler, University of British Columbia
 - Timing is Everything: How often should we perform endoscopic surveillance?
Marietta Iacucci, University of Calgary
 - Charging the Frontlines: Real world challenges with the new hepatitis C therapy
Hemant Shah, University of Toronto
- CAG co-developed this program with Bristol-Myers Squibb Canada to achieve scientific integrity, objectivity and balance –

08h00-09h30

**†CAG SYMPOSIUM:
IBD Microbiota**
Mackenzie**Learning Objectives:**

At the end of this session participants will be able to:

1. Understand the complexity of dietary-microbiota interactions and the role they play in modulation of intestinal inflammation.
2. Discuss the role of bacterial anti-fungal dysbiosis in IBD.
3. Review the current therapies and levels of evidence regarding therapies targeting the microbiome in IBD.

Co-Chairs: Michael Surette, McMaster University and Elena Verdu, McMaster University

- Diet-Microbiota Interactions in IBD: From basics to clinics
Karen Madsen, University of Alberta
- Beyond Bacterial Dysbiosis: Fungal signature in IBD
Frederic Bushman, University of Pennsylvania
- Microbiota Directed Therapies for IBD: Focus on transplantation
Paul Moayyedi*, McMaster University

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

FRIDAY FEBRUARY 26

| | | |
|-------------|--|-------------------------------|
| | <ul style="list-style-type: none"> Determinants of intestinal permeability in healthy first degree relatives of Crohn's disease patients (Abstract 1) <ul style="list-style-type: none"> W Turpin², D Kevans¹, K Shestopaloff³, M Smith², D Guttman², MS Silverberg¹, W Xu³, A Paterson⁴, K Croitoru¹ ¹Mount Sinai Hospital, Toronto, Ontario; ²University of Toronto, Toronto, Ontario; ³Dalla Lana School of Public Health, Toronto, Ontario; ⁴The Hospital for Sick Children, Toronto, Ontario | |
| 09h30-15h00 | ASGE VIDEO CENTRE & EPORTAL CENTRE (See pages 26-27) | Saint-Charles |
| 09h30-10h00 | Exhibits and Nutrition Break | Le Grand Salon/Hochelagas 1-3 |
| 10h00-11h30 | CAG/CASL POSTGRADUATE COURSE Inpatient Hepatology | Marquette/Jolliet |
| | Learning Objectives: At the end of this session participants will be able to: <ol style="list-style-type: none"> Develop an approach to pre-operative assessment and optimization for the liver patient undergoing non-liver procedures. Apply a stepwise approach in encephalopathy management in their practice. Explore the benefits and risks of therapies for alcoholic hepatitis. | |
| | Co-Chairs: Hemant Shah, University of Toronto and Jeffrey So, Halton Healthcare <ul style="list-style-type: none"> Preparing the Patient with Liver Disease for Surgery: Risk assessment and optimization Rohit Loomba, University of California, San Diego Reducing the Confusion around Managing Hepatic Encephalopathy: Update on treatment Philip Wong, McGill University Controversies and Clarity in Managing Acute Alcoholic Hepatitis Meredith Borman, University of Calgary <ul style="list-style-type: none"> CAG co-developed this program with Bristol-Myers Squibb Canada to achieve scientific integrity, objectivity and balance – | |
| 10h00-11h30 | †CAG/CROHN'S AND COLITIS CANADA STUDENT PRIZE PAPER PRESENTATIONS | Mackenzie |
| | Co-Chairs: Aida Fernandes, Crohn's and Colitis Canada (CCC) and François Boudreau, Université de Sherbrooke | |
| | CAG Student Prize <ul style="list-style-type: none"> Integrin $\alpha 1\beta 1$ is controlled by the MYC oncogenic factor and confers pro-proliferative and pro-migratory advantage to colorectal cancer cells (Abstract 2) <ul style="list-style-type: none"> S Boudjadi², G Bernatchez², B Senicourt¹, M Beauséjour², PH Vachon², J Carrier², J Beaulieu² ¹Université de Sherbrooke, Sherbrooke, Québec; ²Anatomie et Biologie Cellulaire, Université de Sherbrooke, Sherbrooke, Québec | |
| | CAG Student Prize <ul style="list-style-type: none"> Role of the phosphatase DUSP6 in the control of intestinal tumorigenesis and inflammation (Abstract 3) <ul style="list-style-type: none"> K Beaudry, A Montagne, M Langlois, S Cagnol, N Rivard Université de Sherbrooke, Sherbrooke, Québec | |
| | CAG Student Prize <ul style="list-style-type: none"> Fecal immunochemical testing and fecal calprotectin predict mucosal healing in inflammatory bowel disease: A prospective study (Abstract 4) <ul style="list-style-type: none"> C Ma, R Lumb, RR Foshaug, T Dang, S Verma, V Huang, KI Kroeker, K Wong, LA Dieleman, BP Halloran, R Fedorak University of Alberta, Edmonton, Alberta | |
| | CCC Student Prize <ul style="list-style-type: none"> The interaction between NOD2 and smoking is specific to the 1007fs SNP of the NOD2 gene in Crohn's disease: A systematic review and meta-analysis (Abstract 5) <ul style="list-style-type: none"> E Kuenzig³, B Eksteen², HW Barkema³, C Seow², C Barnabe², MS Silverberg¹, P Lakatos⁵, R Panaccione², S Ghosh², GG Kaplan⁴ | |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

¹Mount Sinai Hospital, Toronto, Ontario; ²University of Calgary, Calgary, Alberta; ³Community Health Sciences, University of Calgary, Calgary, Alberta; ⁴Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta; ⁵Semmelweis University, Budapest, Hungary

CCC Student Prize

- Intravenous immunoglobulin-induced regulatory macrophages produce IL-10 and may be useful to treat inflammatory bowel disease (**Abstract 6**)
– L Kozicky, S Menzies, LM Sly
University of British Columbia, Vancouver, British Columbia

10h00-11h30

†CAG SELECTED CLINICAL PRESENTATIONS

Duluth

Learning Objectives:

At the end of this session participants will be able to:

1. Explore innovations in the clinical care of patients with complex gastrointestinal disease.
2. Evaluate new information related to advances in the treatment of gastrointestinal diseases.
3. Recognize new directions in research into the management and care of patients with GI illness.

Co-Chairs: Grigorios Leontiadis, McMaster University and Jill Timmouth, University of Toronto

- Trends in incidence of pediatric inflammatory bowel disease in Canada: Population-based estimates from the Canadian Gastro-intestinal Epidemiology Consortium (CanGIEC) (**Abstract 7**)
– El Benchimol^{1,2}, CN Bernstein³, A Bitton⁴, MW Carroll¹, W El-Matary³, A Otley⁵, H Singh³, GC Nguyen⁷, A Griffiths⁷, DR Mack², N Mojaverian², M Vutcovici⁴, Y Cui⁵, Z Nugent³, D Tanyingoh⁶, GG Kaplan⁶
¹University of Alberta, Edmonton, Alberta; ²University of Ottawa, Ottawa, Ontario; ³University of Manitoba, Winnipeg, Manitoba; ⁴Royal Victoria Hospital, McGill University, Montréal, Québec; ⁵Pediatrics, Dalhousie University, Halifax, Nova Scotia; ⁶Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta; ⁷University of Toronto, Toronto, Ontario
 - Steroid-free remission among Canadian pediatric inflammatory bowel disease patients (**Abstract 8**)
– PC Church¹, T Walters¹, El Benchimol⁶, K Jacobson², W El-Matary³, C Deslandres⁴, H Huynh⁵, M Carroll⁵, E Wine⁵, DR Mack⁶, J Van Limbergen⁷, A Otley⁷, A Griffiths¹
¹The Hospital for Sick Children, Toronto, Ontario; ²BC Children's Hospital, Vancouver, British Columbia; ³University of Manitoba, Winnipeg, Manitoba; ⁴Service de gastro-entérologie, Hôpital Sainte-Justine, Montréal, Québec; ⁵Stollery Children's Hospital, Edmonton, Alberta; ⁶Pediatrics, University of Ottawa/CHEO, Ottawa, Ontario; ⁷Pediatric Gastroenterology and Nutrition, IWK Health Centre, Halifax, Nova Scotia
 - A randomized comparison of high definition colonoscopy alone with high definition dye spraying chromoendoscopy and electronic virtual chromoendoscopy using iSCAN for detection of colonic dysplastic lesions during IBD surveillance (**Abstract 9**)
– M Iacucci¹, M Fort Gasia¹, R Panaccione¹, A Oluseyi¹, S Urbanski², M Parham², S Ghosh¹
¹Gastroenterology and ²Department of Pathology – University of Calgary, Calgary, Alberta
 - A virtual reality curriculum in non-technical skills improves performance in colonoscopy: A randomized trial (**Abstract 10**)
– SC Grover¹, MA Scaffidi¹, B Chana¹, K Gupta¹, M Zasowski¹, O Zarghom¹, C Dargavel¹, T Alomani¹, A Kamani¹, S Sharma¹, CM Walsh²
¹Gastroenterology, University of Toronto, Toronto, Ontario; ²Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children and The Wilson Centre, Toronto, Ontario
 - Cost-effectiveness of Hemospray™ in patients with non variceal upper gastrointestinal bleeding (**Abstract 11**)
– AN Barkun^{*}, V Adam, Y Chen, Y Lu, M Martel
McGill University, Montréal, Québec
 - New oral anticoagulants and gastrointestinal hemorrhage: A systematic review and meta-analysis (**Abstract 12**)
– A Dorreen¹, C Miller³, M Martel², AN Barkun³
¹Dalhousie University, Halifax, Nova Scotia; ²McGill University Health Center, Montréal, Québec; ³Gastroenterology, McGill University, The Montreal General Hospital, GI Division, Montréal, Québec
- CAG co-developed this program with Ferring Pharmaceuticals to achieve scientific integrity, objectivity and balance –

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

FRIDAY FEBRUARY 26

| | | |
|-------------|---|-------------------------------|
| 11h30-12h30 | Exhibits and Lunch | Le Grand Salon/Hochelagas 1-3 |
| 12h30-14h30 | <p>CAG/CASL POSTGRADUATE COURSE Safety Monitoring</p> <hr/> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. List addressable causes of interval colon cancers and adapt their endoscopic practices accordingly. 2. Compare and contrast the risk-benefits of long-term proton pump inhibitor use. 3. Appreciate the possible impact of carbapenem-resistant <i>Enterobacteriaceae</i> on current endoscopic disinfection processes. <hr/> <p>Co-Chairs: Alan Barkun*, McGill University and Dan Sadowski, University of Alberta</p> <ul style="list-style-type: none"> • Interval Colon Cancer: How many cancers are we missing and why? Linda Rabeneck*, Colon Cancer Ontario • Long-Term Risks of Proton Pump Inhibitors: What should I tell my patient? Grigorios Leontiadis, McMaster University • How to Keep your Endoscopy Unit out of the Headlines Adam Slivka, University of Pittsburgh | Marquette/Jolliet |
| 12h30-14h30 | <p>†CAG SYMPOSIUM: Cellular Reprogramming in Gastrointestinal Diseases</p> <hr/> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Outline new and cutting edge techniques that facilitate the study of GI disease. 2. Describe new approaches to grow and manipulate GI epithelia as well as intestinal stem cells. 3. Use 3D cell cultures and organoids to answer key questions in GI research. <hr/> <p>Co-Chairs: Nathalie Perreault, Université de Sherbrooke and Bruce Vallance, University of British Columbia</p> <ul style="list-style-type: none"> • Manipulating Gastric Organoids in the Study of Gastric Pathophysiology following Infection Nicola Jones, University of Toronto • The gut microbiota-dependent metabolite, TMAO, protects against colitis: A role for the inhibition of apoptosis? (Abstract 13) – A Al Rajabi, A Wang, DM McKay University of Calgary, Calgary, Alberta • Three-dimensional Organotypic Culture to Study Esophageal Diseases Marie-Pier Tetreault, Northwestern University • Effects of milk lipid globule membrane on post-natal intestinal development (Abstract 14) – G Bhinder, R Dyer, S Innis, B Vallance University of British Columbia, Vancouver, British Columbia • Defining the Structure of the Intestinal Ecosystem by Host-microbial Interactions Thaddeus Stappenbeck, Washington University in St. Louis | Mackenzie |
| 14h30-15h00 | Exhibits and Nutrition Break | Le Grand Salon/Hochelagas 1-3 |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

| | |
|-------------|--|
| 15h00-16h30 | <p>CAG/CASL POSTGRADUATE COURSE Video Endoscopy</p> <p>Marquette/Jolliet</p> <hr/> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Describe three techniques for improved visualization of dysplasia during colonoscopy and discuss ways to implement changes in their own practice to improve dysplasia detection. 2. Outline the potential benefits and challenges of peroral endoscopic myotomy (POEM) vs. surgical or balloon dilation approach to achalasia. 3. Explore how to implement recent advances in endoscopic training into their endoscopic practice. <hr/> <p>Co-Chairs: Lawrence Hookey, Queen's University and Kevin Waschke, McGill University</p> <ul style="list-style-type: none"> • Advances in Endoscopic Imaging and Diagnosis Ralf Kiesslich, Johannes Gutenberg University of Mainz • POEM: The New Standard for the Treatment of Achalasia? Robert Bechara, Queen's University • Advances in Endoscopic Imaging Kevin Waschke |
| 15h00-16h30 | <p>CAG SYMPOSIUM: †Colonic Motility</p> <p>Mackenzie</p> <hr/> <p>Learning Objectives: At the end of this session participants will:</p> <ol style="list-style-type: none"> 1. Recognize the latest developments in high resolution manometry of the human colon and its clinical significance. 2. Be aware of the current hypotheses as to mechanisms underlying colonic motility in animal models and humans. 3. Describe the intrinsic and extrinsic innervation of the colon, its role in motility control and changes occurring during inflammation. <hr/> <p>Co-Chairs: Christopher Andrews, University of Calgary and Jan Huizinga, McMaster University</p> <ul style="list-style-type: none"> • Resolving Colonic Dysmotility Using High Resolution Colonic Manometry Philip Dinning, Flinders University, South Australia • Mechanisms Underlying Colonic Motility Jan Huizinga • Mesotrypsin evokes PAR2 dependent excitability of nociceptive dorsal root ganglia (DRG) neurons (Abstract 15) – CD Lopez Lopez¹, JO Jaramillo Polanco¹, C Rolland-Fourcade², N Vergnolle², S Vanner¹ ¹Gastrointestinal Diseases Research Unit, Queen's University, Kingston, Ontario; ²INSERM UMR-1043, Toulouse, France • Neural Regulation of Colonic Motility Alan Lomax, Queen's University |
| 16h30-17h30 | <p>CAG ANNUAL GENERAL MEETING</p> <p>Mackenzie</p> |
| 16h30-17h30 | <p>CASL ANNUAL GENERAL MEETING</p> <p>Duluth</p> |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

FRIDAY FEBRUARY 26

17h30-18h30

CDDW™ OPENING RECEPTION

Le Grand Salon/Hochelagas 1-3

The conference showcases the latest, cutting-edge products, equipment and services for gastroenterology clinicians and researchers. Exhibitors include companies from the pharmaceutical and food industry as well as the device/instrumentation sector, not-for-profits, and charitable organizations. We invite you to help us open the meeting, take time to get to know the exhibitors and their offerings, and catch up with colleagues while enjoying complimentary drinks and hors d'œuvres. ***Give a note of thanks to our sponsors and exhibitors as without their critical support this meeting would not be possible!*** While at each exhibit booth have your badge scanned to be entered into a contest for a chance to win 1 of 12 room nights at the Fairmont Banff Springs (base room and taxes) for CDDW™ 2017.

18h30-20h00

TRAINEE MIXER

Saint-Maurice

New this year we are offering trainees the opportunity to mix and mingle with others who are at a similar stage in their career development. Whether you are a graduate student, medical student, resident or post-doctoral fellow, come meet your colleagues from across Canada to compare notes on your research, career aspirations or next steps. We respectfully ask that only trainees take part in this mixer. Light snacks and beverages (bring your drink tickets) will be served.

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

SATURDAY FEBRUARY 27

| | | |
|--|---|------------|
| 07h00-08h00 | Challenges in Gastroenterology and GI Research – Open Mic Session Come lend your voice to identify and brainstorm solutions to the key issues facing digestive health care and GI research in Canada. Last year's session provided useful direction to CAG's Human Resources Task Force; help us continue their initiative and expand the focus while enjoying a hot breakfast. | Duluth |
| 07h00-09h00 | Morning Coffee , supported by the Canadian Digestive Health Foundation | Booth 2001 |
| 08h00-09h00 | CAG BREAKFAST WITH THE EXPERTS Celiac Disease: Case based | Chaudière |
| Learning Objectives: At the end of this session participants will be able to: <ol style="list-style-type: none"> 1. Describe the association of celiac disease with other autoimmune disorders. 2. List the differential diagnosis in patients with celiac disease when there are conflicting investigations. 3. Identify the appropriate treatment monitoring in celiac disease. | | |
| Speakers: Mohsin Rashid, Dalhousie University and Alaa Rostom, University of Ottawa Please note that pre-registration is required to gain admittance to Breakfast with the Experts | | |
| 08h00-09h00 | CAG BREAKFAST WITH THE EXPERTS Barrett's Esophagus | Matapédia |
| Learning Objectives: At the end of this session, participants will be able to: <ol style="list-style-type: none"> 1. Recognize the role of the various modalities used in the diagnosis and staging of high-grade dysplasia and early esophageal adenocarcinoma. 2. Identify the indications, benefits and complications of the available endoscopic techniques in the treatment of high-grade dysplasia and early neoplasm. 3. Appreciate the need for adequate long-term follow-up of patients successfully treated by endoscopic ablation. | | |
| Speakers: Ralf Kiesslich, Johannes Gutenberg University of Mainz and Serge Mayrand, McGill University Please note that pre-registration is required to gain admittance to Breakfast with the Experts | | |
| 08h00-09h00 | CASL BREAKFAST WITH THE EXPERTS Difficult Autoimmune Liver Disease (AILD) Cases | Harricana |
| Learning Objectives: At the end of this session, participants will be able to: <ol style="list-style-type: none"> 1. Recognize the effects of IBD on primary sclerosing cholangitis outcomes. 2. Be aware of the role of IgG4 in biliary disease. 3. Discuss the use of rituximab in complex AILD. | | |
| Speakers: Angela Cheung, University of Toronto and Bertus Eksteen, University of Calgary Please note that pre-registration is required to gain admittance to Breakfast with the Experts | | |
| 08h00-10h00 | †CAG SYMPOSIUM: Epigenetics of Gastrointestinal Cancer | Mackenzie |
| Learning Objectives: At the end of this session participants will be able to: <ol style="list-style-type: none"> 1. Identify the role of epigenetics in the development and progression of GI cancers. 2. List potential epigenetic biomarkers and therapeutic targets for GI cancers. 3. Describe how nutritional epigenetics influences GI cancers. | | |
| Co-Chairs: Young-In Kim, University of Toronto and Isabella Tai, University of British Columbia | | |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

- Role of Epigenetics in the Development and Progression of GI Cancers
Daniel Weisenberger, University of Southern California
- Epigenetics as a Prognostic Indicator and Therapeutic Target for GI Cancers
Bharati Bapat, University of Toronto
- Nutritional Epigenetics: A mechanistic link between nutrition and GI cancers?
Young-In Kim
- VacA-disrupted autophagy promotes accumulation of *Helicobacter pylori* cytotoxin associated gene a during chronic infection (**Abstract 16**)
– M Abdullah¹, LK Greenfield¹, M Capurro¹, C O'Brien², N Jones¹
¹Cell Biology Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario; ²Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario
- The role of SHP-1 as a tumor suppressor gene in intestinal epithelium (**Abstract 17**)
– C Leblanc, G Coulombe, N Rivard
Université de Sherbrooke, Sherbrooke, Québec

08h30-10h00

†CASL PAPER SESSION 1

Duluth

Learning Objectives:

At the end of this session participants will be able to:

1. Explore innovations in the clinical care of patients with complex liver disease.
2. Evaluate new information related to advances in the treatment of liver disease.
3. Recognize new directions in research into the management and care of patients with liver disease.

Co-Chairs: Mark Swain, University of Calgary and Eric Yoshida*, University of British Columbia

CASL Student Prize

- Prevalence and factors associated with nonalcoholic fatty liver disease as diagnosed by transient elastography with controlled attenuation parameter in HIV mono-infected patients (**Abstract 18**)
– E Vuille-Lessard, L Lennox, C Pexos, B Lebouche, MB Klein, G Sebastiani
Royal Victoria Hospital, McGill University Health Center, Montréal, Québec
- Minimal hepatic encephalopathy renders the brain susceptible to hypotension-induced neuronal cell loss in BDL rats (**Abstract 19**)
– M Clément¹, CR Bosoi¹, M Tremblay¹, C Bemeur², CF Rose¹
¹CRCHUM, Montréal, Québec; ²Nutrition, Université de Montréal, Montréal, Québec
- Risk factors and outcomes of non-skin cancers after liver transplantation for primary sclerosing cholangitis (**Abstract 20**)
– MA Mouchli, S Singh, JA Talwalkar, EV Loftus, C Rosen, J Heimbach, RH Wiesner, K Watt, JJ Poterucha
Mayo Clinic, Rochester, Minnesota
- Cirrhotic patients with sarcopenia and sarcopenic-obesity have an increased risk of hyperammonemia and hepatic encephalopathy (**Abstract 21**)
– AJ Montano-Loza³, A Duarte-Rojo⁴, RA Bhanji², CF Rose¹
¹Hôpital St-Luc, CRCHUM, Université de Montréal, Montréal, Québec; ²University of Alberta, Edmonton, Alberta; ³Division of Gastroenterology & Liver Unit, University of Alberta, Edmonton, Alberta; ⁴University of Arkansas for Medical Sciences, Little Rock, Arkansas
- Reduced hepatic PGC-1α leads to oxidative stress and worsened NAFLD progression (**Abstract 22**)
– A Besse-Patin, JL Estall
Mécanismes Moléculaires du Diabète, Institut de Recherches Cliniques de Montréal, Montréal, Québec
- Post-transplant cholestasis within 1-year predicts PSC recurrence (**Abstract 23**)
– S Wasilenko¹, E Lytvak², AJ Montano-Loza², AL Mason²
¹University of Alberta, Edmonton, Alberta; ²Division of Gastroenterology & Liver Unit, University of Alberta, Edmonton, Alberta
– CAG co-developed this program with Lupin Pharma Canada Ltd. to achieve scientific integrity, objectivity and balance –

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

| | | |
|---|--|---|
| 09h00-10h00 | <p>CAG SYMPOSIUM</p> <p>Precision Medicine as an Emerging Theme in Gastroenterology</p> <hr/> <p>Learning Objectives:</p> <p>At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Consider the implications for new biomarkers to tailor the care of digestive disorders in Canada in the coming decade. 2. Recognize how best to stay updated and maintain the skill-set required for gastroenterology healthcare providers in 2020. <hr/> <p>Co-Chairs: Jonathan Meddings, University of Calgary and Philip Sherman, Canadian Institutes of Health Research</p> <ul style="list-style-type: none"> • Update: CIHR Institute of Nutrition, Metabolism and Diabetes Refreshed Strategic Plan 2015-2018 Philip Sherman • The Future of Precision Medicine in Gastroenterology Jane Aubin, Canadian Institutes of Health Research • How will Precision Medicine Change Education and Research in Gastroenterology? Nicola Jones, University of Toronto <ul style="list-style-type: none"> – CAG co-developed this program with the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes to achieve scientific integrity, objectivity and balance – | Marquette/Jolliet |
| 10h00-10h30 | <p>CLF-CASL GOLD MEDAL LECTURE</p> <p>A Personal Journey Through the History of Hepatology: The Role of Good Fortune</p> <p>Morris Sherman*, University of Toronto</p> <p>– Introduction by Eberhard Renner</p> | Marquette/Jolliet |
| 10h30-15h30 | ASGE VIDEO CENTRE & EPORTAL CENTRE (See pages 26-27) | Saint-Charles |
| 10h30-11h00 | Exhibits and Nutrition Break | Le Grand Salon/Hochelagas 1-3 |
| 11h00-11h40 | <p>SMALL GROUP SESSIONS (See details on pages 28-34)</p> <p>SEE (Skills Enhancement for Endoscopy): Practical tips (CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance)</p> <p>SEE: Practical tips (CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance)</p> <p>Investigation of the Small Bowel (CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance)</p> <p>Ultrasound and IBD (CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance)</p> <p>Refractory Encopresis in Pediatrics</p> <p>Work-Life Balance Issues</p> <p>Interventional EUS (CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance)</p> <p>Infection Models</p> <p>Case Discussions in Pediatric Chronic Viral Hepatitis (CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance)</p> <p>Thrombosis and Liver Disease - When to anticoagulate</p> <p>HIV and Liver Transplant - Outcomes, barriers and what to expect</p> | <p>Richelieu</p> <p>Gatineau</p> <p>Bersimis</p> <p>Saint Laurent</p> <p>Kamouraska 1+2</p> <p>Ramezay</p> <p>Péribonka</p> <p>Youville 1+2</p> <p>Chaudière</p> <p>Matapédia</p> <p>Harricana</p> |
| Please note that pre-registration is required to gain admittance to Small Group Sessions | | |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

SATURDAY FEBRUARY 27

| | | |
|-------------|--|--------------------------------------|
| 11h40-11h50 | Break | |
| 11h50-12h30 | <p>SMALL GROUP SESSIONS (See details on pages 28-34)</p> <p>SEE: Practical tips (CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance)</p> <p>Updates in Fecal Microbiota Transplant</p> <p>Colonic Motility</p> <p>Early Onset IBD in Pediatrics (CAG co-developed this program with Janssen Inc. to achieve scientific integrity, objectivity and balance)</p> <p>Marijuana and GI Disease</p> <p>Colonic Polypectomy (CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance)</p> <p>CDHF Session: Protecting the Human Gut Microbiota to Enhance Health (CAG co-developed this program with Shire Pharma Canada ULC to achieve scientific integrity, objectivity and balance)</p> <p>Acute on Chronic Liver Failure - When is the patient too sick for transplant?</p> <p>Lean Non-alcoholic Fatty Liver Disease (NAFLD) - Is it Different than Obese NAFLD?</p> <p>Intermediate Stage HCC - What to Do?</p> <p style="text-align: right;">Richelieu</p> <p style="text-align: right;">Saint Laurent</p> <p style="text-align: right;">Kamouraska 1+2</p> <p style="text-align: right;">Bersimis</p> <p style="text-align: right;">Ramezay</p> <p style="text-align: right;">Pérignonka</p> <p style="text-align: right;">Youville 1+2</p> <p style="text-align: right;">Chaudière</p> <p style="text-align: right;">Matapédia</p> <p style="text-align: right;">Harricana</p> <p style="text-align: center;">Please note that pre-registration is required to gain admittance to Small Group Sessions</p> | |
| 12h30-13h30 | Exhibits and Lunch | Le Grand Salon/Hochelagas 1-3 |
| 13h30-15h00 | <p>CIHR-CAG SYMPOSIUM</p> <p>The Role of Nutrition in Gastroenterology</p> <hr/> <p>Learning Objectives:</p> <p>At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Describe dietary interventions for GI symptoms and food intolerance. 2. Be aware of the low-FODMAP diet. 3. Have insight into a holistic analysis of eating patterns as opposed to a more "bean counting approach". 4. Discuss case-based strategies to combat malnutrition in hospitalized patients. <hr/> <p>Co-Chairs: Leah Gramlich, University of Alberta and Khursheed Jeejeebhoy, University of Toronto</p> <ul style="list-style-type: none"> • Bloating, Functional Bowel Disease and Food Sensitivity: Non-celiac gluten sensitivity, the low FODMAP diet and beyond? Low FODMAP diet and the future of food intolerance Peter Gibson, Monash University • The Practical Dietary Guidelines Jean-Claude Moubarac, Université de Montréal • The Role of the Gastroenterologist in Hospital Malnutrition Leah Gramlich and Khursheed Jeejeebhoy <p style="text-align: center;">– CAG co-developed this program with the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes to achieve scientific integrity, objectivity and balance –</p> | Marquette/Jolliet |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

SATURDAY FEBRUARY 27

| | | |
|-------------|---|-------------------------------|
| 13h30-15h00 | <p>CASL SYMPOSIUM Updates in Pediatric Cholestasis</p> <hr/> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Identify the role of non-invasive markers of fibrosis and inflammation in primary sclerosing cholangitis. 2. Recognize recent advances in the genetics and therapeutics of progressive familial intrahepatic cholestasis. 3. Explore physiological roles, and therapeutic targets, for bile acid-mediated regulation of metabolism in liver and intestine that impact upon NAFLD and cholestatic disorders. <hr/> <p>Co-Chairs: Binita Kamath, University of Toronto and Richard Schreiber, University of British Columbia</p> <ul style="list-style-type: none"> • Primary Sclerosing Cholangitis: Monitoring and surveillance for teens in the modern era Bertus Eksteen, University of Calgary • Updates in Progressive Familial Intrahepatic Cholestasis Binita Kamath • Bile Acid-based Therapeutics for Liver and Obesity-related Disorders Saul Karpen, Emory University | Duluth |
| 13h30-15h00 | <p>RESEARCH CAREER DEVELOPMENT</p> <hr/> <p>Learning Objectives: At the end of this session participants will:</p> <ol style="list-style-type: none"> 1. Have a better understanding of career paths inside and outside of academia. 2. Be better equipped to seek and secure a productive post-doctoral fellowship. 3. Be able to recognize and foster the development of marketable skills beyond those learned in the lab. <hr/> <p>Co-Chairs: Simon Hirota, University of Calgary and Martin Stahl, University of British Columbia</p> <ul style="list-style-type: none"> • How to Get the Most Out of Your Postdoctoral Fellowship Simon Hirota/Martin Stahl • Views from Industry: Insight into a career outside of academia Ryan Conder, STEMCELL Technologies • I am a Scientist and I Play One on TV Jennifer Gardy, University of British Columbia | Mackenzie |
| 15h00-15h30 | Exhibits and Nutrition Break | Le Grand Salon/Hochelagas 1-3 |
| 15h30-16h30 | <p>KOPEMAN LECTURE Pediatric IBD: Integrating clinical care and research</p> <p>Anne Griffiths, University of Toronto – Introduction by Decker Butzner</p> | Mackenzie |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

| | | |
|-------------|---|-------------------------------|
| 15h30-17h00 | <p>CAG SYMPOSIUM Monitoring Disease Activity in IBD</p> <hr/> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Recognize the role of patient experience and identify the utility of patient report approaches in the assessment of disease activity in patients with IBD. 2. Identify the operating characteristics of serum and fecal inflammatory biomarkers for assessment of disease activity in patients with IBD. 3. Determine the role of endoscopic and radiologic evaluation in the assessment of disease activity in patients with IBD. <hr/> <p>Co-Chairs: Waqqas Afif, McGill University and Charles Bernstein*, University of Manitoba</p> <ul style="list-style-type: none"> • Stress, Clinical Symptoms and Patient Report in the Assessment of Disease Activity in IBD Lesley Graff, University of Manitoba • Serum and Stool Markers in the Assessment of Disease Activity in IBD Edward Loftus*, Mayo Clinic, Rochester • Radiology and Endoscopy in the Assessment of Disease Activity in IBD Talat Bessissow, McGill University • Panel Discussion/Cases – CAG co-developed this program with AbbVie to achieve scientific integrity, objectivity and balance – | Marquette/Jolliet |
| 15h30-17h00 | <p>CASL SYMPOSIUM Optimizing Fatty Liver Outcomes</p> <hr/> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Evaluate the evidence base for current fatty liver treatments. 2. Recognize the role of non-medical management for nonalcoholic steatohepatitis. 3. Appreciate that fatty liver is more than a liver disease. <hr/> <p>Co-Chairs: Melanie Beaton, Western University and Saumya Jayakumar, University of Calgary</p> <ul style="list-style-type: none"> • Treatment Options for NAFLD: Current and practical management considerations for your practice Rohit Loomba, University of California, San Diego • Bariatric Surgery for NAFLD Bandar Al-Judaibi, Western University • Extrahepatic Complications of NAFLD Keyur Patel, University of Toronto | Duluth |
| 17h00-17h30 | MCKENNA RECEPTION | Conference Level Foyer |
| 17h30-18h30 | <p>RD MCKENNA MEMORIAL LECTURE Working on the Barrier Johan Söderholm, Linköping University – Introduction by Derek McKay</p> <p>Immediately preceding the McKenna Lecture there will be a short presentation of the Canadian Association of Gastroenterology Fellows (CAGF) inducted for 2016. CAGF is an esteemed honour for CAG members who have demonstrated long-term commitment to the Association and to furthering the goals of advancing gastroenterology practice and GI research in Canada</p> | Marquette/Jolliet |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

SATURDAY FEBRUARY 27

18h30-20h00

POSTER SESSION 1

Hochelagas 4-6/Saguenay/Saint-Maurice

Join authors and colleagues in relaxed and informative discussions while enjoying beverages and light snacks. Please be sure to see the Posters of Distinction (A35, A82, A100, A115-A123, A152, A156) located throughout the poster area and identified with a ribbon.

| | | |
|-------------|--|-----------|
| 08h00-09h00 | <p>CAG BREAKFAST WITH THE EXPERTS Difficult Cases in Crohn's Disease</p> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Identify options for assessing for postoperative recurrence of Crohn's disease. 2. Recognize the utility of therapeutic drug monitoring in individuals with recurrent Crohn's disease on biologic therapy. 3. Discuss medical options for individuals with anti-TNF refractory (or anti-TNF intolerant) Crohn's disease. <p>Speakers: Edward Loftus*, Mayo Clinic, Rochester and Chad Williams, Saint John</p> <p>Please note that pre-registration is required to gain admittance to Breakfast with the Experts</p> <p>– CAG co-developed this program with Janssen Inc. to achieve scientific integrity, objectivity and balance –</p> | Chaudière |
| 08h00-09h00 | <p>CAG BREAKFAST WITH THE EXPERTS Advances in <i>Helicobacter pylori</i> Therapeutics</p> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Describe the two main new CAG/Canadian Helicobacter Study Group recommended options for first line therapy of <i>H. pylori</i> infection. 2. Explain choices for second line therapy depending on the treatment that previously failed. 3. Recognize the treatment algorithm for <i>H. pylori</i> as recommended by the CAG/Canadian Helicobacter Study Group. <p>Speakers: Naoki Chiba, McMaster University and Carlo Fallone, McGill University</p> <p>Please note that pre-registration is required to gain admittance to Breakfast with the Experts</p> | Matapédia |
| 08h00-09h00 | <p>CASL BREAKFAST WITH THE EXPERTS HRS and SBP: Tips and tricks</p> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Identify best practices in managing hepatorenal syndrome and spontaneous bacterial peritonitis. 2. Review common pitfalls in management and develop strategies that address them. <p>Speakers: Puneeta Tandon, University of Alberta and Cynthia Tsien, University of Toronto</p> <p>Please note that pre-registration is required to gain admittance to Breakfast with the Experts</p> | Harricana |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

08h30-10h30

†CAG SYMPOSIUM:
Innate Mucosal Immunology

Mackenzie

Learning Objectives:

At the end of this session participants will be able to:

1. Describe the role of the inflammasome in gut inflammation.
2. Recognize the contribution of macrophages to innate immune driven inflammation.
3. Explain the role of NOD2 in inflammation and IBD.

Co-Chairs: Samantha Gruenheid, University of British Columbia and Laura Sly, University of British Columbia

- SHIP Regulates IL-1 β Transcription in Macrophages and Intestinal Autoinflammation
Laura Sly
- *Entamoeba histolytica*-induced Inflammasome Activation and its Role in Intestinal Pathogenesis
Kris Chadee, University of Calgary
- Role of ATG16L1 in Bacterial Autophagy - Link with Crohn's disease
Dana Philpott, University of Toronto
- A multicenter, double-blind, placebo-controlled Ph3 study of ustekinumab, a human monoclonal antibody to IL-12/23P40, in patients with moderately-severely active Crohn's disease who are naïve or not refractory to anti-TNF α : UNITI-2 (**Abstract 24**)
– BG Feagan², C Gasink⁶, Y Lang⁶, J Friedman⁶, J Johanns⁶, L Gao⁶, BE Sands¹, S Hanauer³, P Rutgeerts⁷, S Targan⁸, S Ghosh⁴, W de Villiers⁹, JF Colombel¹, Z Tulassay¹⁰, U Seidler¹¹, W Sandborn⁵
¹Mount Sinai Medical Center, New York, New York; ²Robarts Clinical Trials Inc, London, Ontario;
³Northwestern University, Chicago, Illinois; ⁴University of Calgary, Calgary, Alberta; ⁵UCSD, La Jolla, California; ⁶Janssen R & D, LLC, Spring House, Pennsylvania; ⁷University Hospital Gasthuisberg, Leuven, Belgium; ⁸Cedars-Sinai Medical Center, Los Angeles, California; ⁹University of Cape Town, Cape Town, South Africa; ¹⁰Semmelweis University, Budapest, Hungary; ¹¹Hannover Medical School, Hannover, Germany
- Small intestinal bacteria determine gluten metabolism and immunogenicity (**Abstract 25**)
– A Caminero Fernandez¹, H Galipeau², J McCarville¹, C Johnston¹, S Bernier¹, A Russell⁴, J Jury¹, J Casqueiro Blanco³, J Tye-Din⁴, M Surette¹, N Magarvey¹, E Verdu¹
¹McMaster University, Hamilton, Ontario; ²Medical Sciences, McMaster University, Hamilton, Ontario;
³Universidad De Leon, Leon, Castilla y Leon, Spain; ⁴The Walter And Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

09h00-10h30

CAG SYMPOSIUM
Luminal Signaling to Nerves in Functional Disorders: Pathophysiological and clinical implications

Marquette/Joliet

Learning Objectives:

At the end of this session participants will be able to:

1. Recognize the relationship between stress, the microbiota, and intestinal inflammation.
2. Describe how luminal factors can modulate sensory nerve signaling from the intestine.
3. Discuss the role of clinical treatments targeting luminal factors in the management of functional bowel disorders.

Co-Chairs: Premysl Bercik, McMaster University and Stephen Vanner, Queen's University

- Interplay of Stress, Gut Microbiota and Inflammation
Michael Bailey, Ohio State University
- Luminal Signaling to Colonic Afferent Nerves
David Reed, Queen's University
- Clinical Treatments Targeting Luminal Signaling in Functional Disorders
Stephen Vanner

| | | |
|-------------|---|---|
| 09h00-10h30 | <p>†CASL PAPER SESSION 2</p> <p>Co-Chairs: Alnoor Ramji, University of British Columbia and Hemant Shah, University of Toronto</p> <p>CASL Student Prize</p> <ul style="list-style-type: none"> • Characterization of hepatitis B virus (HBV) lymphotropism and immune status in chronic hepatitis B (CHB) pregnant carriers (Abstract 26) <ul style="list-style-type: none"> – <u>DC Wong</u>, S Gao, S Joshi, T Matwi, G Samadi Kochaksaraei, G Bindra, G van Marle, SR Martin, E Castillo, CS Coffin <i>University of Calgary, Calgary, Alberta</i> • End-of-life healthcare costs and utilization among patients with end-stage-liver-disease in Ontario: A population-based study (Abstract 27) <ul style="list-style-type: none"> – <u>EM Kelly</u>³, S Murthy³, F Wong¹, T Shaw-Stiffel³, L Scully³, M Chalifoux², P Tanuseputro², P James³ ¹<i>Medicine, Toronto General Hospital, Toronto, Ontario;</i> ²<i>OHRI, Ottawa, Ontario;</i> ³<i>Department of Medicine, The Ottawa Hospital, Ottawa, Ontario</i> • Protective immunity upon HCV reinfection is associated with selection of memory CD8 T cell clonotypes with the highest functional avidity (Abstract 28) <ul style="list-style-type: none"> – <u>M Boisvert</u>¹, MS Abdel-Hakeem¹, J Bruneau², H Soudeyns³, N Shoukry¹ ¹<i>Centre de recherche du CHUM,</i> ²<i>Centre hospitalier de l'Université de Montréal, and</i> ³<i>Département de microbiologie, infectiologie et immunologie, Université de Montréal – Montréal, Québec</i> • Developing a prognostic model for significant liver fibrosis in HIV-hepatitis C (HCV) co-infected individuals from the Canadian co-infection cohort study (Abstract 29) <ul style="list-style-type: none"> – <u>N Moqueet</u>¹, C Kanagaratham², D Radzioch², S Saeed³, RW Platt¹, MB Klein⁴ ¹<i>Epidemiology, Biostatistics, and Occupational Health, McGill University,</i> ²<i>Department of Medicine and Department of Human Genetics, McGill University,</i> ³<i>Epidemiology, Biostatistics, and Occupational Health, McGill University, and</i> ⁴<i>Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre – Montréal, Québec</i> • Ornithine phenylacetate attenuates loss of muscle mass and improves hepatic encephalopathy in bile-duct ligated rats (Abstract 30) <ul style="list-style-type: none"> – <u>CR Boso</u>², M Oliveira¹, M Clément¹, M Tremblay¹, G Ten Have³, N Deutz³, CF Rose¹ ¹<i>CRCHUM and</i> ²<i>IRCM, Montréal, Québec;</i> ³<i>Texas A&M University, College Station, Texas</i> • Protein-calorie malnutrition is prevalent among cirrhotic patients awaiting liver transplant as measured by direct estimates of protein and calorie intake as well as both subjective and objective tools (Abstract 31) <ul style="list-style-type: none"> – <u>KJ Marr</u>², A Shaheen², L Lam³, M Stapleton², KW Burak¹, M Raman² ¹<i>Liver Unit, University of Calgary, Calgary, Alberta;</i> ²<i>University of Calgary, Calgary, Alberta;</i> ³<i>Alberta Health Services, Calgary, Alberta</i> | Duluth |
| 10h30-15h30 | ASGE VIDEO CENTRE & EPORTAL CENTRE (See pages 26-27) | Saint-Charles |
| 10h30-11h00 | Exhibits and Nutrition Break | Le Grand Salon/Hochelagas 1-3 |
| 11h00-11h40 | <p>SMALL GROUP SESSIONS (See pages 28-34)</p> <p>SEE: Practical tips (CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance)</p> <p>SEE: Practical tips (CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance)</p> <p>Exclusive Enteral Nutrition in Pediatrics</p> <p>Endoscopy in Bariatric Patients (CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance)</p> <p>Managing Difficult Constipation</p> <p>Immunization in IBD (CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance)</p> | <p>Richelieu</p> <p>Gatineau</p> <p>Ramezay</p> <p>Péribonka</p> <p>Bersimis</p> <p>Saint Laurent</p> |

SUNDAY FEBRUARY 28

| | | |
|-------------|--|--|
| | <p>Patient-centred Care in Endoscopy</p> <p>Bioinformatics and the Microbiome (CAG co-developed this program with Shire Pharma Canada ULC to achieve scientific integrity, objectivity and balance)</p> <p>Ultrashort Treatments for HCV (CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance)</p> <p>Designing and Delivering Effective Education Sessions</p> <p>Drug-Induced Liver Injury - Are there any therapies to try?</p> <p style="text-align: center;">Please note that pre-registration is required to gain admittance to Small Group Sessions</p> | <p>Kamouraska 1+2</p> <p>Youville 1+2</p> <p>Chaudière</p> <p>Matapédia</p> <p>Harricana</p> |
| 11h40-11h50 | Break | |
| 11h50-12h30 | <p>SMALL GROUP SESSIONS (See pages 28-34)</p> <p>SEE: Practical tips (CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance)</p> <p>Intractable Abdominal Pain in Children - Management options</p> <p>Is this Food Intolerance or Food Allergy?</p> <p>Unusual Causes of Abdominal Pain</p> <p>Arthralgias in IBD (CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance)</p> <p>Patient-centred Care in IBD (CAG co-developed this program with Janssen Inc. to achieve scientific integrity, objectivity and balance)</p> <p>Competency by Design/CanMEDS 2015</p> <p>Antibody-Mediated Rejection after Liver Transplant</p> <p>Pulmonary Complications of Cirrhosis</p> <p>Can We Ever Stop Nucleoside Analogue Therapy for HBV?</p> <p style="text-align: center;">Please note that pre-registration is required to gain admittance to Small Group Sessions</p> | <p>Richelieu</p> <p>Ramezay</p> <p>Péribonka</p> <p>Bersimis</p> <p>Saint Laurent</p> <p>Kamouraska 1+2</p> <p>Youville 1+2</p> <p>Chaudière</p> <p>Matapédia</p> <p>Harricana</p> |
| 12h30-13h30 | Exhibits and Lunch | Le Grand Salon/Hochelagas 1-3 |
| 13h30-15h00 | <p>CAG SYMPOSIUM</p> <p>Rapid Fire 2015 Journal Review</p> <hr/> <p>Learning Objectives:</p> <p>At the end of this session participants will be:</p> <ol style="list-style-type: none"> 1. Familiar with many of the highest impact articles in clinical gastroenterology in 2015. 2. Able to decide whether selected publications answer their clinical needs. 3. Able to see if they agree with their peers. <hr/> <p>Faculty: Desmond Leddin, Dalhousie University and David Morgan, McMaster University</p> <p>Use a clicker to vote on multiple-choice questions and test your knowledge of the key papers and findings from 2015!</p> | Duluth |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

| | |
|-------------|---|
| 13h30-15h00 | <p>CASL SYMPOSIUM Saint-Laurent/Gatineau</p> <p>Hepatocellular Carcinoma (HCC): Controversies in surveillance, diagnosis and management</p> <hr/> <p>Learning Objectives:</p> <p>At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Analyze the role of alpha-fetoprotein in HCC surveillance. 2. Identify clinical scenarios where contrast enhanced ultrasound is useful for HCC diagnosis. 3. Discuss controversies in HCC management in a Canadian context. <hr/> <p>Co-Chairs: Kelly Burak, University of Calgary and Kevork Peltekian, Dalhousie University</p> <ul style="list-style-type: none"> • Should Alpha-Fetoprotein be used with Ultrasonography for HCC Surveillance? Amit Singal, University of Texas Southwestern Medical Centre • How Can Contrast Enhanced Ultrasound Assist in the Diagnosis of HCC? Stephanie Wilson, University of Calgary • Controversies in Management of HCC (Update from CASL HCC Meeting) Kelly Burak |
| 13h30-15h00 | <p>CAG RESEARCH AWARD LECTURES Mackenzie</p> <p>CAG YOUNG INVESTIGATOR AWARD LECTURE</p> <p>The Proteomics of Colorectal Cancer: Identification of a protein signature associated with prognosis</p> <p>François-Michel Boisvert, Université de Sherbrooke</p> <p>– Introduction by Nathalie Rivard</p> <p>CAG RESEARCH EXCELLENCE AWARD LECTURE</p> <p>Host-Microbe Interactions in the Gut: The epithelium calls the tune!</p> <p>Bruce Vallance, University of British Columbia</p> <p>– Introduction by Deanna Gibson</p> |
| 15h00-15h30 | <p>Exhibits and Nutrition Break Le Grand Salon/Hochelagas 1-3</p> |
| 15h30-17h00 | <p>CAG SYMPOSIUM Duluth</p> <p>Diarrhea and Constipation: Slow, slow, quick, quick, slow: The colonic tango</p> <hr/> <p>Learning Objectives:</p> <p>At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Recognize the importance of microbiota in regulation of colonic function and sensation. 2. Improve their understanding of colonic motility through state-of-the-art diagnostic technology. 3. Describe the latest technological and pharmacologic treatments for constipation and diarrhea. <hr/> <p>Co-Chairs: Christopher Andrews, University of Calgary and Paul Moayyedi*, McMaster University</p> <ul style="list-style-type: none"> • What is the Role of Microbiome in Influencing Bowel Habit? Premysl Bercik, McMaster University • Is there a Technological Solution to Constipation? Philip Dinning, Flinders University, South Australia • Pharmacological Options for Chronic Constipation and Diarrhea: Now and in the future Christopher Andrews <ul style="list-style-type: none"> – CAG co-developed this program with Allergan Canada to achieve scientific integrity, objectivity and balance – |

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

| | | |
|-------------|--|------------------------|
| 15h30-17h00 | <p>CASL SPECIAL CONFERENCE Hepatitis C Virus Update</p> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Develop an approach to easy and complex HCV treatment scenarios. 2. Evaluate resistance testing and its growing role in management of HCV. 3. Appreciate the technical aspects and challenges of economic analysis for HCV therapies. <p>Co-Chairs: Curtis Cooper, University of Ottawa and Jordan Feld, University of Toronto</p> <ul style="list-style-type: none"> • Treating HCV is Easy, Except When It Is Hard Alnoor Ramji, University of British Columbia • Relevance and Risks of Resistance Richard Harrigan, BC Centre for Excellence in HIV/AIDS • The Immunology of the Transition from Acute to Chronic Viral Hepatitis Antonio Bertolotti, Duke-Nus Medical School, Singapore – CAG co-developed this program with AbbVie to achieve scientific integrity, objectivity and balance – | Saint-Laurent/Gatineau |
| 15h30-17h00 | <p>†CAG SYMPOSIUM: New Technologies</p> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Evaluate how novel genomics approaches can be used for drug and biomarker discovery for colorectal cancer. 2. Determine what novel genomic and integrative approaches can be used to identify the key biological pathways that not only explain susceptibility to common diseases but also the basis of disease heterogeneity. 3. Explain how data-dependent and targeted proteomic analyses work, how the results can be integrated with genomic/transcriptomic type data and how proteomics can reveal biological processes that are not accessible by genomic analysis strategies. <p>Co-Chairs: François-Michel Boisvert, Université de Sherbrooke and Eytan Wine, University of Alberta</p> <ul style="list-style-type: none"> • miR-142-3p and vitamin D-mediated regulation of autophagy: Linking environmental gene interactions in IBD (Abstract 32) – F Dang², A Hsieh², I Verpalen², R Murchie², LK Greenfield², M Abdullah², D Philpott³, N Jones¹ ¹The Hospital for Sick Children, Toronto, Ontario; ²Cell Biology, The Hospital for Sick Children, Toronto, Ontario; ³University of Toronto, Toronto, Ontario • High Throughput Genomics in the Search for Novel Therapies and Biomarkers to Advance Management of Colorectal Cancer Isabella Tai, University of British Columbia • Going from Genetic Association to a Better Biologic Understanding and Treatment of Inflammatory Bowel Diseases John Rioux, Université de Montréal • Proteogenomic Analyses of Colorectal Carcinoma Robbert Slebos, Vanderbilt University Medical School | Mackenzie |
| 17h00-18h00 | <p>2016 CDDW™ AWARDS CEREMONY</p> <p>We invite you to join us at the annual Awards Ceremony to congratulate and celebrate with the many awardees as awards from the Associations are formally presented.</p> | St. François |

SUNDAY FEBRUARY 28

18h00-19h30

POSTER SESSION 2

Hochelagas 4-6/Saguenay/Saint Maurice

Join authors and colleagues in relaxed and informative discussions while enjoying beverages and light snacks. Please be sure to see the Posters of Distinction (A193-A197, A208, A214, A229, A230, A247-A253, A315, A331) located throughout the poster area and identified with a ribbon.

20h00-23h30

GALA EVENT

Marquette/Jolliet/Duluth

Centre Ice Gala

Pull on your favourite hockey jersey, and enjoy the company of fellow hockey fans as CDDW™ hosts the “Centre Ice Gala”. Treat your taste buds to the most exotic stadium cuisine, test out your stick handling skills, and skate the night away with tunes from our own Power Play DJ. Purchase tickets (\$100 + tax) online and also at registration on-site.

* American College of Gastroenterology Fellow or Master

† Session includes oral presentations of key abstracts

| | |
|-------------|---|
| 08h00-09h00 | <p>CAG BREAKFAST WITH THE EXPERTS Difficult Cases in Ulcerative Colitis</p> <p style="text-align: right;">Saint-Maurice</p> <hr/> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Recognize the need for second-line therapy in acute severe colitis. 2. Assess drug levels and optimize dosing of anti-TNF levels. 3. Identify poor prognostic markers in ulcerative colitis. <hr/> <p>Speakers: Marla Dubinsky, Mount Sinai Hospital, New York and Adam Weizman, University of Toronto</p> <p style="text-align: center;">Please note that pre-registration is required to gain admittance to Breakfast with the Experts</p> <p style="text-align: center;">– CAG co-developed this program with Janssen Inc. to achieve scientific integrity, objectivity and balance –</p> |
| 09h00-10h30 | <p>CAG SYMPOSIUM 2015 Papers That Influenced Your Practice</p> <p style="text-align: right;">Duluth</p> <hr/> <p>Learning Objectives: At the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Consider strategies for implementing therapeutic drug monitoring in IBD management and understand the relationship between biologic drug trough levels and IBD activity. 2. Describe the clinical implications of attempting to treat patients with advanced cirrhosis, including decompensated cirrhosis, with antiviral agents. 3. Recognize the impact of standardized management strategies on IBD outcomes and understand the risk-benefit trade-off of early immunosuppressive therapy for IBD. <hr/> <p>Speakers: John Marshall, McMaster University and Eric Yoshida*, University of British Columbia</p> <p><i>The format for this interactive session is that speakers will present three pivotal papers from 2015, providing a 15-minute review of the paper, followed by 10-15 minutes for questions and audience discussion/interaction.</i></p> <p>Papers</p> <ul style="list-style-type: none"> • Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. <i>Gastroenterology</i> 2015;148(7):1320-9. – John Marshall • Charlton M, Everson, GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. <i>Gastroenterology</i> 2015;149(3): 649-59. – Eric Yoshida* • Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): A cluster randomised controlled trial. <i>Lancet</i>. 2015 Sep 2. pii: S0140-6736(15)00068-9. – John Marshall <p style="text-align: center;">– CAG co-developed this program with Takeda Canada, Inc. to achieve scientific integrity, objectivity and balance –</p> |

MONDAY FEBRUARY 29

| | | |
|-------------|---|--|
| 09h00-10h30 | <p>CASL SYMPOSIUM The Future of Hepatology - Diseases and their Cures - Reality or Science Fiction?</p> <hr/> <p>Learning Objectives: At the end of this session participants will:</p> <ol style="list-style-type: none"> 1. Recognize how HBV immunology impacts therapeutic choices now and in the future. 2. Appreciate research into liver stem cells and the 3D liver as important to the future of hepatology. 3. Evaluate how curative therapies impact HCC screening in the future. <hr/> <p>Co-Chairs: Carla Coffin, University of Calgary and Philip Wong, McGill University</p> <ul style="list-style-type: none"> • Age-Dependent Events during HBV Infections: Implications for therapy Antonio Bertolotti, Duke-Nus Medical School, Singapore • Liver Stem Cells and 3D Artificial Liver Shinichiro Ogawa, University of Toronto • Future of HCC Screening in the Era of Potent Antivirals for HCV, HBV and the Rise of NASH/NAFLD-related Liver Disease Morris Sherman*, University of Toronto <p style="text-align: center;">– CAG co-developed this program with Gilead Sciences Canada, Inc. to achieve scientific integrity, objectivity and balance –</p> | Mackenzie |
| 10h30-11h00 | Nutrition Break | Foyer |
| 11h00-11h40 | <p>SMALL GROUP SESSIONS (See pages 28-34)</p> <p>Approach to Uninvestigated Dysphagia</p> <p>Case-based Anticoagulation</p> <p>Oral Anticoagulants and Cirrhotic Patients – Safety and monitoring</p> <p style="text-align: center;">Please note that pre-registration is required to gain admittance to Small Group Sessions</p> | <p>Saint-Laurent</p> <p>Gatineau</p> <p>Bersimis</p> |
| 11h40-11h50 | Break | |
| 11h50-12h30 | <p>SMALL GROUP SESSIONS (See pages 28-34)</p> <p>Non-invasive Monitoring of Liver Disease (CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance)</p> <p>Managing Chronic Pancreatitis: It's more than just abstinence</p> <p style="text-align: center;">Please note that pre-registration is required to gain admittance to Small Group Sessions</p> | <p>Saint-Laurent</p> <p>Gatineau</p> |
| 12h30-13h30 | Lunch | Foyer |

13h30-15h00

CAG SYMPOSIUM

Duluth

Therapeutics in IBD: Past, present and future

Learning Objectives:

At the end of this session participants will be able to:

1. Identify appropriate (and/or inappropriate) use of steroids and immunosuppressants in the treatment of IBD.
 2. Describe optimal use of biologic therapies in the treatment of IBD.
 3. Recognize the role of a personalized approach to treatment of IBD.
-

Co-Chairs: Alain Bitton, McGill University and Sharyle Fowler, University of Saskatchewan

- Should We Still Be Using Steroids and Immunosuppressants to Treat IBD?
John Marshall, McMaster University
 - Current and Upcoming Biologics for Treating IBD
Subrata Ghosh, University of Calgary
 - The Future of IBD Therapy: A personalized approach
Marla Dubinsky, Mount Sinai Hospital, New York
- CAG co-developed this program with Janssen Inc. to achieve scientific integrity, objectivity and balance –



American Society for Gastrointestinal Endoscopy (ASGE) Video Centres

At the ASGE Video Centre, located in Saint-Charles, delegates can rotate at their own pace through three video stations which demonstrate endoscopic techniques and technologies. All nine videos are from the ASGE Endoscopic Learning Library collection.

FRIDAY FEBRUARY 26

Station 1 – Radial and Linear EUS

Richard A. Erickson, MD, Brenna C. Bounds, MD, Lawrence Lai, MRCP, William R. Brugge, MD, Mauritz Wiersema, MD, Michael Kochman, MD, Lisa Wiersema, MD
Total run time: 97 minutes

Station 2 – Endoscopic Approach to Hemorrhoids

Rome Jutabha, MD, Tonya Kaltenbach, MD, Roy Soetikno, MD
Total run time: 28 minutes

Station 3 – Diagnostic and Therapeutic Endoscopy in Patients after Ileal Pouch Surgery

Francis A. Farraye, MD, MSc, FASGE, Bo Shen, MD, FASGE
Total run time: 65 minutes

SATURDAY FEBRUARY 27

Station 1 – Biliary Access Techniques for ERCP: From Basic to Advanced

Martin L. Freeman MD; Kapil Gupta, MD, MPH
Total run time: 63 minutes

Station 2 – Small Bowel Imaging

Klaus E. Monkemuller, MD, PhD, FASGE, Marzena Zabielski, RN, BSN, Lucia C. Fry, MD, FASGE, and Helmut Neumann, MD, PhD
Total run time: 40 minutes

Station 3 – Polyposis Syndrome/Genetic GI: Endoscopic Diagnosis and Management

Vinay Chandrasekhara, MD, Anil K. Rustgi, MD, Timothy C. Hoops, MD, Michael L. Kochman, MD, FASGE, Gregory G. Ginsberg, MD, FASGE
Total run time: 60 minutes

SUNDAY FEBRUARY 28

Station 1 – Endoscopic Submucosal Dissection of Colon Lateral Spreading Tumour

Won Young Cho, MD, Bong Min Ko, MD, Gene Hyun Bok, MD, Kwang Yeun Shim, MD, Hyun Gun Kim, PhD, Tae Hee Lee, MD, Suck Ho Lee, MD, So Young Jin, MD, and Joo Young Cho, MD
Total run time: 36 minutes

Station 2 – Endoscopic Interpretation and Therapy of Severe Lower GI Bleeding

Roy Soetikno, MD; Tonya Kaltenbach, MD; Peter Kelsey, MD; Kenneth McQuaid MD, FASGE
Total run time: 33 minutes

Station 3 – EUS-Guided Biliary Drainage: Current Techniques

Vinay Dhir, MD, Takao Itoi, MD, Amit Maydeo, MD
Total run time: 30 minutes

The CAG is grateful to the ASGE for this learning opportunity
Please visit <http://www.asge.org/> to order videos

Participants may claim Section 2 Personal Learning Project credits as defined by
the Royal College of Physicians and Surgeons of Canada

CAG Educational Portal (ePortal) Learning Centre at CDDW™ 2016

Visit the ePortal Learning Center in the Saint-Charles Room to Access a Wide Variety of Educational Materials!

The following are just a few of the MANY outstanding videos to choose from:

from the CDDW™ 2015 Program

CAG/CASL Postgraduate Course – IBD and Nutrition

- Nutritional Deficiencies in IBD- What is the significance? – *Dr. Khursheed Jeejeebhoy*
- Nutrition and the Gut Biome-What is the impact in IBD? – *Dr. Levinus Dieleman*

CAG Symposium – Working with the Bugs

- Not So Unculturable: Recent advances in cultivating the human gut microbiome – *Dr. Michael Surette*
- Probiotics: Where are we and where are we going? – *Dr. Karen Madsen*
- Fecal Microbiota Transplant Past, Present and Future – *Dr. Christina Surawicz*

McKenna Memorial Lecture: Fifty Years of Gastroenterology: a personal reflection- *Dr. Don Powell*

from The CAG Basic Science and CanMEDS Lecture Series

- Dr. Waqqas Afif – Health Advocacy/Choosing Wisely for the IBD Patient – September 2015
- Dr. Louis Liu – Constipation with a Focus on Motility/Anorectal studies – December 2015
- Dr. Hemant Shah – Pre-operative Surgical Risk in Liver Patients – January 2016

from the 2015 GI Symposium: Microbes, IBD and Other GI Diseases

- Managing Psychological Aspects of IBD – *Dr. Lesley Graff*
- Approach to post-operative Crohn's Disease – *Dr. Laura Targownik*
- Current Thinking on the Pathogenesis of IBD – *Dr. Claudio Fiocchi*

Visit the ePortal by logging in to MYCAG

CAG members may log in with their member email and password

CDDW™ participants may claim **Section 2** self-learning credits as defined by the Royal College of Physicians and Surgeons of Canada (RCPSC)

| | | |
|--------------|------------------------------|--------------------|
| Open: | Friday, February 26 | 09h30-15h00 |
| | Saturday, February 27 | 10h30-15h30 |
| | Sunday, February 28 | 10h30-15h30 |

***The CAG is a Recipient of the 2012 Royal College Accredited
CPD Provider Innovation Award for the ePortal***

Small Group Sessions

Small group sessions (limit of up to 35 attendees) are 40-minute interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. For room allocations see pages 34-39. **Pre-registration required.**

| | Saturday 27 th | | Sunday 28 th | | Monday 29 th | |
|---|---------------------------|-------|-------------------------|-------|-------------------------|-------|
| | 11h00 | 11h50 | 11h00 | 11h50 | 11h00 | 11h50 |
| SATURDAY | | | | | | |
| SEE: Practical tips ----- | ◆ | ◆ | | | | |
| Investigation of the Small Bowel----- | ◆ | | | | | |
| Ultrasound and IBD----- | ◆ | | | | | |
| Refractory Encopresis in Pediatrics----- | ◆ | | | | | |
| Work-Life Balance Issues ----- | ◆ | | | | | |
| Interventional EUS ----- | ◆ | | | | | |
| Infection Models ----- | ◆ | | | | | |
| Case Discussions in Pediatric Chronic Viral Hepatitis----- | ◆ | | | | | |
| Thrombosis and Liver Disease - When to anticoagulate----- | ◆ | | | | | |
| HIV and Liver Transplant - Outcomes, barriers and what to expect----- | ◆ | | | | | |
| Updates in Fecal Microbiota Transplant ----- | | ◆ | | | | |
| Colonic Motility----- | | ◆ | | | | |
| Early Onset IBD in Pediatrics----- | | ◆ | | | | |
| Marijuana and GI Disease ----- | | ◆ | | | | |
| Colonic Polypectomy----- | | ◆ | | | | |
| CDHF Session: Protecting the Human Gut Microbiota to Enhance Health----- | | ◆ | | | | |
| Acute on Chronic Liver Failure - When is the patient too sick for transplant? ----- | | ◆ | | | | |
| Lean NAFLD - Is it different than obese NAFLD? ----- | | ◆ | | | | |
| Intermediate Stage HCC - What to do?----- | | ◆ | | | | |
| SUNDAY | | | | | | |
| SEE: Practical tips ----- | | | ◆ | ◆ | | |
| Exclusive Enteral Nutrition in Pediatrics ----- | | | ◆ | | | |
| Endoscopy in Bariatric Patients----- | | | ◆ | | | |
| Managing Difficult Constipation----- | | | ◆ | | | |
| Immunization in IBD ----- | | | ◆ | | | |
| Patient-centred Care in Endoscopy----- | | | ◆ | | | |
| Bioinformatics and the Microbiome ----- | | | ◆ | | | |
| Ultrashort Treatments for HCV----- | | | ◆ | | | |
| Designing and Delivering Effective Education Sessions----- | | | ◆ | | | |
| Drug-Induced Liver Injury - Are there any therapies to try? ----- | | | ◆ | | | |
| Intractable Abdominal Pain in Children - Management options ----- | | | | ◆ | | |
| Is this Food Intolerance or Food Allergy? ----- | | | | ◆ | | |
| Unusual Causes of Abdominal Pain ----- | | | | ◆ | | |
| Arthralgias in IBD----- | | | | ◆ | | |
| Patient-centred Care in IBD ----- | | | | ◆ | | |
| Competence by Design/CanMEDS 2015----- | | | | ◆ | | |
| Antibody-Mediated Rejection after Liver Transplant ----- | | | | ◆ | | |
| Pulmonary Complications of Cirrhosis ----- | | | | ◆ | | |
| Can We Ever Stop Nucleoside Analogue Therapy for HBV? ----- | | | | ◆ | | |
| MONDAY | | | | | | |
| Approach to Uninvestigated Dysphagia----- | | | | | ◆ | |
| Case-based Anticoagulation----- | | | | | ◆ | |
| Oral Anticoagulants and Cirrhotic Patients - Safety and monitoring ----- | | | | | ◆ | |
| Non-invasive Monitoring of Liver Disease----- | | | | | | ◆ |
| Managing Chronic Pancreatitis: It's more than just abstinence ----- | | | | | | ◆ |

Small Group Sessions

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. **Pre-registration required.**

- **SEE: Practical tips** **Saturday and Sunday, February 27 & 28, 11h00 & 11h50 (Richelieu)**
Learning Objectives: 1) Demonstrate how scope handling influences colonoscopy technique, 2) Demonstrate how to apply torque steering during colonoscopy, 3) Demonstrate how to integrate changes in handling and torque into one's colonoscopy technique.
Speakers: Lawrence Hookey, Queen's University and Alaa Rostom, University of Ottawa (Saturday 11h00); Frances Tse, McMaster University and Kevin Waschke, McGill University (Saturday 11h50); Eric Greenwald, McMaster University and Donald MacIntosh, Dalhousie University (Sunday 11h00); Mark Borgaonkar*, Memorial University and Alaa Rostom, University of Ottawa (Sunday 11h50)
CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance
- **SEE: Practical tips** **Saturday and Sunday, February 27 & 28, 11h00 (Gatineau)**
Learning Objectives: 1) Demonstrate how scope handling influences colonoscopy technique, 2) Demonstrate how to apply torque steering during colonoscopy, 3) Demonstrate how to integrate changes in handling and torque into one's colonoscopy technique.
Speakers: David Armstrong*, McMaster University and Dana Farina, Dalhousie University (Saturday); Frances Tse, McMaster University and Kevin Waschke, McGill University (Sunday)
CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance
- **Investigation of the Small Bowel** **Saturday, February 27, 11h00 (Bersimis)**
Learning Objectives: 1) Understand key conditions that result in obscure GI bleeding, 2) Identify which instruments are ideal to investigate the small bowel and 3) Recognize limitations – advantages and disadvantages – of various instruments for small bowel evaluation.
Speakers: Robert Enns, University of British Columbia and Christopher Teshima, University of Toronto
CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance
- **Ultrasound and IBD** **Saturday, February 27, 11h00 (Saint-Laurent)**
Learning Objectives: 1) Understand the pros/cons of different imaging modalities available today for both diagnosis and monitoring of patients with IBD, 2) Recognize four key sonographic components of active IBD, review a simple score for disease activity (Simple Ultrasonographic Score/SUS) and identify complications of IBD on bowel ultrasound, 3) Understand how ultrasound may be used in clinical decision-making, and 4) Recognize how ultrasound can be used in the future as a clinical tool to differentiate between IBS and IBD in patients referred for symptoms such as diarrhea.
Speakers: Cathy Lu, University of Alberta and Kerri Novak, University of Calgary
CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance
- **Refractory Encopresis in Pediatrics** **Saturday, February 27, 11h00 (Kamouraska 1+2)**
Learning Objectives: 1) Identify the difference between retentive and non-retentive fecal incontinence in children, 2) Describe the initial steps in management of a child with fecal incontinence, 3) Assess the need for additional investigations and referral to other allied health members in children with refractory fecal incontinence, and 4) Recognize the global impact of refractory fecal incontinence on the child and family's quality of life.
Speakers: Dominique Levesque, McGill University and Alfred Yeung, University of Calgary
- **Work-Life Balance Issues** **Saturday, February 27, 11h00 (Ramezay)**
Learning Objectives: 1) Identify work-life balance issues present in the practice of gastroenterology/medicine, 2) Describe features of physician burnout, 3) Identify issues within the healthcare system that contribute to work-life imbalance, and 4) Describe resources/strategies available to decrease burnout and improve balance and resilience.
Speakers: Melanie Beaton, Western University and Lana Bistriz, University of Alberta
- **Interventional EUS** **Saturday, February 27, 11h00 (Péribonka)**
Learning Objectives: 1) Review the indications, efficacy and techniques of EUS-guided celiac plexus block and neurolysis, 2) Discuss the evidence and technical advances in EUS-guided pancreatic fluid collection drainage, 3) Comment on the role of EUS-guided fiducial placement in radiation therapy, and 4) Identify the indications and risks associated with EUS bilio-pancreatic access and drainage.
Speakers: Charles Ménard, Université de Sherbrooke and Frances Tse, McMaster University
CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance

Small Group Sessions Continued

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. **Pre-registration required.**

- **Infection Models** **Saturday, February 27, 11h00 (Youville 1+2)**
Learning Objectives: 1) Describe the various infection models used in IBD research, 2) Recognize the strengths and limitations of each of the models, and 3) Identify areas for further innovation and development.
Speakers: Brian Coombes, McMaster University and Deanna Gibson, University of British Columbia
- **Case Discussions in Pediatric Chronic Viral Hepatitis** **Saturday, February 27, 11h00 (Chaudière)**
Learning Objectives: 1) Discuss common viral hepatitis scenarios in the pediatric population, and 2) Identify how new therapies for viral hepatitis could be applied to the pediatric population.
Speakers: Simon Ling, University of Toronto and Steven Martin, University of Calgary
CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance
- **Thrombosis and Liver Disease - When to anticoagulate** **Saturday, February 27, 11h00 (Matapédia)**
Learning Objectives: 1) Appreciate both the anticoagulant and procoagulant factors that can be abnormal in patients with cirrhosis, and 2) Develop an approach to the management and choice of anticoagulants for thrombotic conditions in cirrhotic patients including portal vein thrombosis, deep vein thrombosis, and pulmonary embolism.
Speakers: Aman Arya, University of Toronto and Jennifer Flemming, Queen's University
- **HIV and Liver Transplant - Outcomes, barriers and what to expect** **Saturday, February 27, 11h00 (Harricana)**
Learning Objective: Be aware of the indications and outcomes of liver transplantation in HIV positive recipients.
Speakers: Eberhard Renner, University of Toronto and Eric Yoshida*, University of British Columbia
- **Updates in Fecal Microbiota Transplant** **Saturday, February 27, 11h50 (Saint-Laurent)**
Learning Objectives: 1) Describe current pediatric and adult evidence for fecal microbial transplantation (FMT) in the management of recurrent *Clostridium difficile* infection, 2) Discuss current pediatric and adult evidence for the role of FMT in the management of Crohn's disease and ulcerative colitis, 3) Assess patient eligibility for FMT and identify potential risks, and 4) Describe Health Canada regulations concerning FMT.
Speakers: Dina Kao, University of Alberta and Nikhil Pai, McMaster University
- **Colonic Motility** **Saturday, February 27, 11h50 (Kamouraska 1+2)**
Learning Objectives: 1) Recognize common patterns of colonic motility, 2) Identify indications for colonic manometry studies in children, adolescents and adults, and 3) Evaluate the pros and cons of different motor function tests currently employed.
Speakers: Jan Huizinga, McMaster University and Elyanne Ratcliffe, McMaster University
- **Early Onset IBD in Pediatrics** **Saturday, February 27, 11h50 (Bersimis)**
Learning Objectives: 1) Describe current experience with potential therapeutic options for children with primary anti-TNF failure, 2) Recognize limitations of current diagnostic modalities, and 3) Identify children who would benefit from first-line biological therapeutics.
Speakers: David Mack, University of Ottawa and Anthony Otley, Dalhousie University
CAG co-developed this program with Janssen Inc. to achieve scientific integrity, objectivity and balance
- **Marijuana and GI Disease** **Saturday, February 27, 11h50 (Ramezay)**
Learning Objectives: 1) Recognize the prevalence and patterns of use of cannabis by patients with GI diseases, 2) Assess the evidence base for cannabinoid use in GI disorders, and 3) Discuss the barriers and facilitators for authorizing the clinical use of cannabinoids in GI disease.
Speakers: Constantine Soulellis, McGill University and Mark Ware, McGill University

Small Group Sessions Continued

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. **Pre-registration required.**

- **Colonic Polypectomy** **Saturday, February 27, 11h50 (Péribonka)**
Learning Objectives: 1) Describe morphological assessment of polyps according to the Paris Classification, 2) Assess laterally spreading polyps for safe and efficient endoscopic mucosal resection (EMR), 3) Identify critical aspects of EMR technique, and 4) Recognize and manage EMR-related complications.
Speakers: Paul Kortan*, University of Toronto and Donald MacIntosh, Dalhousie University
CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance
- **CDHF Session: Protecting the Human Gut Microbiota to Enhance Health** **Saturday, February 27, 11h50 (Youville 1+2)**
Learning Objectives: 1) Explain how the human gut microbiota impacts digestive and overall health, and 2) Recognize risk factors that may negatively impact a healthy gut microbiota.
Speakers: David Armstrong*, McMaster University and Richard Hunt*, Canadian Digestive Health Foundation
CAG co-developed this program with Shire Pharma Canada ULC to achieve scientific integrity, objectivity and balance
- **Acute on Chronic Liver Failure - When is the patient too sick for transplant?** **Saturday, February 27, 11h50 (Chaudière)**
Learning Objectives: 1) Define acute on chronic liver failure, 2) Establish a prognosis, and 3) Determine transplant candidacy.
Speakers: Vince Bain, University of Alberta and Paul Marotta, Western University
- **Lean NAFLD - Is it different than obese NAFLD?** **Saturday, February 27, 11h50 (Matapédia)**
Learning Objectives: 1) Describe the different risk factors for development of NASH in the lean adult population, and understand how this may be a different pathophysiologic mechanism than obese NASH, 2) Be able to have a treatment algorithm for management of patients with lean NASH, 3) Understand which children with NAFLD actually have 'lean NAFLD', and 4) Be able to diagnose and treat patients with lean NAFLD secondary to syndromes or other conditions that affect lipid metabolism.
Speakers: Saumya Jayakumar, University of Calgary and Marialena Mouzaki, University of Toronto
- **Intermediate Stage HCC - What to do?** **Saturday, February 27, 11h50 (Harricana)**
Learning Objectives: 1) Recognize intermediate stage HCC, 2) Understand the research behind the recommended treatments, and 3) Identify what treatments are not optimal.
Speakers: Kelly Burak, University of Calgary and Morris Sherman*, University of Toronto
- **Exclusive Enteral Nutrition in Pediatrics** **Sunday, February 28, 11h00 (Ramezay)**
Learning Objectives: 1) Recognize the unique features and advantages of exclusive enteral nutrition (EEN) in treating patients with pediatric IBD, 2) Describe potential mechanisms of action of EEN, 3) Discuss novel future variations on nutritional therapy and potential applications to understanding IBD pathogenesis and treatment, and 4) Identify the crucial role of allied health professionals in successful implementation of an enteral nutrition program.
Speakers: Anthony Otley, Dalhousie University and Eytan Wine, University of Alberta
- **Endoscopy in Bariatric Patients** **Sunday, February 28, 11h00 (Péribonka)**
Learning Objectives: 1) Define the role of surgery in the morbidly obese patient and understand the different surgical treatment options, 2) Appreciate the clinical outcomes of bariatric surgery and clarify the frequency and severity of complications, and 3) Discuss the indications for endoscopy in bariatric surgical patients and evaluate novel endoscopic strategies for management of morbid obesity.
Speakers: Rajesh Aggarwal, McGill University and Gary May, University of Toronto
CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance
- **Managing Difficult Constipation** **Sunday, February 28, 11h00 (Bersimis)**
Learning Objectives: 1) Describe the evidence for current therapies for constipation in pediatric and adult populations, and 2) Understand the differences in evaluation of constipation between children, adolescents, and adults.
Speakers: Christopher Andrews, University of Calgary and Eylanne Ratcliffe, McMaster University

Small Group Sessions Continued

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. **Pre-registration required.**

- **Immunization in IBD** **Sunday, February 28, 11h00 (Saint-Laurent)**
Learning Objectives: 1) Describe timing of immunizations in IBD patients, 2) Explain the implications of live vaccines to IBD patients, and 3) Identify patients at risk of preventable infections.
Speakers: Marla Dubinsky, Mount Sinai Hospital New York and Sophie Plamondon, Université de Sherbrooke
CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance
- **Patient-centred Care in Endoscopy** **Sunday, February 28, 11h00 (Kamouraska 1+2)**
Learning Objectives: 1) Reflect upon one's own practice using the dimensions of patient-centred care, 2) Be able to discuss the pros and cons of current quality indicators, 3) Initiate a patient-centred quality endoscopy process at one's institution/practice, 4) Challenge oneself to examine something one thinks he/she already knows, and 5) Examine the factors one would use to choose the endoscopist for their own colonoscopy.
Speakers: Catherine Dubé, University of Ottawa and Roger Hollingworth, Credit Valley Hospital
- **Bioinformatics and the Microbiome** **Sunday, February 28, 11h00 (Youville 1+2)**
Learning Objectives: 1) Identify the processes used to convert raw sequence reads into preliminary microbiome analyses, 2) Critically make decisions about steps that will impact the analyses, and 3) Describe the utility of a few different downstream analysis tools.
Speaker: Jennifer Stearns, McMaster University
CAG co-developed this program with Shire Pharma Canada ULC to achieve scientific integrity, objectivity and balance
- **Ultrashort Treatments for HCV** **Sunday, February 28, 11h00 (Chaudière)**
Learning Objectives: 1) Discuss the patient characteristics that would be considered for a short course of therapy, and 2) Explore future potential 'ultra-short' regimens for HCV.
Speakers: Jordan Feld, University of Toronto and Alnoor Ramji, University of British Columbia
CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance
- **Designing and Delivering Effective Education Sessions** **Sunday, February 28, 11h00 (Matapédia)**
Learning Objectives: 1) Identify the principles and factors that contribute to effective adult learning, 2) Develop an approach to the design of effective education sessions, and 3) Appreciate the factors that contribute to effective delivery of education sessions.
Speakers: Catharine Walsh, University of Toronto and Winnie Wong, University of Alberta
- **Drug Induced Liver Injury - Are there any therapies to try?** **Sunday, February 28, 11h00 (Harricana)**
Learning Objective: Review the clinical approach and management strategies for drug-induced liver injury.
Speakers: Constantine Karvellas, University of Alberta
- **Intractable Abdominal Pain in Children - Management options** **Sunday, February 28, 11h50 (Ramezay)**
Learning Objectives: 1) Define intractable abdominal pain within the context of a bio-psychosocial model of care, 2) Identify diagnostic strategies for the detection of subtle intestinal inflammatory disease, 3) Recognize the importance of peripheral and central sensitization to the development of chronic pain, and 4) Assess the need for pharmacological and non-pharmacological interventions in conjunction with the pain-service and clinical psychology.
Speakers: Kevan Jacobson, University of British Columbia and Angela Noble, Queen's University
- **Is this Food Intolerance or Food Allergy?** **Sunday, February 28, 11h50 (Péribonka)**
Learning Objectives: 1) Describe the tests available to diagnose a food allergy, 2) Discuss the limitations associated with commonly used diagnostic tests for food allergy, and 3) Discuss the clinical application of the low FODMAP diet in patients with suspected food intolerances and IBS.
Speakers: Peter Gibson, Monash University and Maitreyi Raman, University of Calgary

Small Group Sessions Continued

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. **Pre-registration required.**

- **Unusual Causes of Abdominal Pain** Sunday, February 28, 11h50 (Bersimis)
Learning Objectives: Have: 1) An approach to managing patients with chronic abdominal pain, 2) An appreciation of some common causes of neuropathic pain in the abdomen, and 3) An understanding of appropriate strategies for an effective referral to a physical therapist.
Speakers: David Armstrong*, McMaster University and Shanker Nesathurai, McMaster University
- **Arthralgias in IBD** Sunday, February 28, 11h50 (Saint-Laurent)
Learning Objectives: 1) Identify different presentations of arthritis in the IBD patient, 2) Develop an understanding and working knowledge of treatment strategies to address the many facets of disease in this patient population, and 3) Optimize cross-specialty referrals.
Speakers: Talat Bessissow, McGill University and Elizabeth Hazel, McGill University
CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance
- **Patient-centred Care in IBD** Sunday, February 28, 11h50 (Kamouraska 1+2)
Learning Objectives: 1) Explore the determinants of patient-centred care in IBD, 2) Identify obstacles to patient-centred care for IBD patients in the physician's own clinical environment, and 3) Determine strategies to promote patient-centred care in the management of IBD patients.
Speakers: Alain Bitton, McGill University and Sylviane Forget, McGill University
CAG co-developed this program with Janssen Inc. to achieve scientific integrity, objectivity and balance
- **Competency by Design/CanMEDS 2015** Sunday, February 28, 11h50 (Youville 1+2)
Learning Objectives: 1) Explain the key components for competence by design for residency education programs, 2) Discuss how milestones and entrustable professional activities will serve to promote learning and assessment across the CanMEDS Roles, and 3) Describe the strategies and tools to support program directors and clinical supervisors prior to and during the transition to competence by design.
Speaker: Craig Campbell, Royal College of Physicians and Surgeons of Canada
- **Antibody-Mediated Rejection after Liver Transplant** Sunday, February 28, 11h50 (Chaudière)
Learning Objective: Review our evolving understanding of antibody-mediated rejection and its impact on post-transplant management.
Speakers: Stephen Congly, University of Calgary and Aldo Montano-Loza, University of Alberta
- **Pulmonary Complications of Cirrhosis** Sunday, February 28, 11h50 (Matapédia)
Learning Objectives: 1) Recognize who needs screening, and how to make the diagnosis, for portopulmonary hypertension and hepatopulmonary syndrome, and know the highlights of management and prognosis, and 2) Describe management options for the challenging clinical problem of hepatic hydrothorax.
Speakers: Jennifer Leonard, Memorial University and Puneeta Tandon, University of Alberta
- **Can We Ever Stop Nucleoside Analogue Therapy for HBV?** Sunday, February 28, 11h50 (Harricana)
Learning Objectives: 1) Discuss the clinical/laboratory variables that indicate a successful course of therapy, and 2) Identify the laboratory test results associated with a long-term quiescent phase of HBV infection.
Speakers: Carla Coffin, University of Calgary and David Wong, University of Toronto
- **Approach to Uninvestigated Dysphagia** Monday, February 29, 11h00 (Saint-Laurent)
Learning Objectives: 1) Describe an approach to evaluate patients presenting with dysphagia, and 2) Recognize the role of upper GI barium study, endoscopy, and esophageal manometry to assess patients with dysphagia.
Speaker: Louis Liu, University of Toronto
- **Case-based Anticoagulation** Monday, February 29, 11h00 (Gatineau)
Learning Objectives: 1) Understand the bleeding risks related to endoscopic procedures, 2) Utilize an evidence-based approach to evaluating a patient's risk of thrombotic events, and 3) Be familiar with the indications for bridging of anticoagulation around endoscopic procedures.
Speakers: Vicky Tagalakis, McGill University and Kevin Waschke, McGill University

Small Group Sessions Continued

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. **Pre-registration required.**

- **Oral Anticoagulants and Cirrhotic Patients - Safety and monitoring** **Monday, February 29, 11h00 (Bersimis)**
Learning Objective: Develop an approach to the use of oral anticoagulants in cirrhotic patients.
Speakers: Meredith Borman, University of Calgary and Carla Coffin, University of Calgary

- **Non-invasive Monitoring of Liver Disease** **Monday, February 29, 11h50 (Saint-Laurent)**
Learning Objectives: 1) Recognize the clinical importance of staging fibrosis for management and prognosis in chronic liver diseases, 2) Identify and describe the different non-invasive modalities to diagnose and monitor liver disease, and 3) Compare and contrast the benefits and limitations of the non-invasive monitoring modalities, such as Fibroscan, Fibrotest, Fib-4 and APRI.
Speakers: Hin Hin Ko, University of British Columbia and Giada Sebastiani, McGill University
CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance

- **Managing Chronic Pancreatitis: It's more than just abstinence** **Monday, February 29, 11h50 (Gatineau)**
Learning Objective: 1) Discuss the medical management of chronic pancreatitis, 2) Evaluate the data on celiac plexus block in the management of chronic pancreatitis, 3) Identify which patients to refer for endoscopic management, and 4) Recognize which patients to refer for surgical management.
Speakers: Michael Cantor, University of Manitoba and Jennifer Telford*, University of British Columbia


CDDW™ 2017

Banff, February 26 – March 8

SUMMARY OF ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA ACCREDITED SECTION 1 CREDITS

| <u>Friday, February 26</u> | <u>Credits</u> | <u>Session Title</u> |
|-------------------------------------|-----------------------|---|
| 08h00-09h30 | 1.5 | CAG/CASL Postgraduate Course: Community-based GI and Liver Disease |
| 08h00-09h30 | 1.5 | IBD Microbiota |
| 10h00-11h30 | 1.5 | CAG/CASL Postgraduate Course: Inpatient Hepatology |
| 10h00-11h30 | 1.5 | CAG Selected Clinical Presentations |
| 10h00-11h30 | 1.5 | CAG/CCC Student Prize Paper Presentations |
| 12h30-14h30 | 2 | CAG/CASL Postgraduate Course: Safety Monitoring |
| 12h30-14h30 | 2 | Cellular Reprogramming in GI Diseases |
| 15h00-16h30 | 1.5 | CAG/CASL Postgraduate Course: Video Endoscopy |
| 15h00-16h30 | 1.5 | Colonic Motility |
| <u>Saturday, February 27</u> | | |
| 08h00-09h00 | 1 | Breakfast with the Experts: Celiac Disease: Case based |
| 08h00-09h00 | 1 | Breakfast with the Experts: Barrett's Esophagus |
| 08h00-09h00 | 1 | Breakfast with the Experts: Difficult AILD Cases |
| 08h00-10h00 | 2 | Epigenetics of Gastrointestinal Cancer |
| 08h30-10h00 | 1.5 | CASL Paper Session 1 |
| 09h00-10h00 | 1 | Precision Medicine as an Emerging Theme in Gastroenterology |
| 10h00-10h30 | 0.5 | CLF-CASL Gold Medal Lecture |
| 11h00-11h40 | 0.75 | Small Group Sessions |
| 11h50-12h30 | 0.75 | Small Group Sessions |
| 13h30-15h00 | 1.5 | The Role of Nutrition in Gastroenterology |
| 13h30-15h00 | 1.5 | Updates in Pediatric Cholestasis |
| 13h30-15h00 | 1.5 | Research Career Development |
| 15h30-16h30 | 1 | Kopelman Lecture |
| 15h30-17h00 | 1.5 | Monitoring Disease Activity in IBD |
| 15h30-17h00 | 1.5 | Optimizing Fatty Liver Outcomes |
| 17h30-18h30 | 1 | McKenna Lecture |
| <u>Sunday, February 28</u> | | |
| 08h00-09h00 | 1 | Breakfast with the Experts: Difficult Cases in Crohn's Disease |
| 08h00-09h00 | 1 | Breakfast with the Experts: Advances in <i>H. pylori</i> Therapeutics |
| 08h00-09h00 | 1 | Breakfast with the Experts: HRS and SBP: Tips and tricks |
| 08h30-10h30 | 2 | Innate Mucosal Immunology |
| 09h00-10h30 | 1.5 | Luminal Signaling to Nerves in Functional Disorders: Pathophysiological and clinical implications |
| 09h00-10h30 | 1.5 | CASL Paper Session 2 |
| 11h00-11h40 | 0.75 | Small Group Sessions |
| 11h50-12h30 | 0.75 | Small Group Sessions |
| 13h30-15h00 | 1.5 | Rapid Fire 2015 Journal Review |
| 13h30-15h00 | 1.5 | HCC: Controversies in surveillance, diagnosis and management |
| 13h30-15h00 | 1.5 | CAG Young Investigator and Research Excellence Lectures |
| 15h30-17h00 | 1.5 | Diarrhea and Constipation: Slow, slow, quick, quick, slow: The colonic tango |
| 15h30-17h00 | 1.5 | New Technologies |
| 15h30-17h00 | 1.5 | HCV Update |
| <u>Monday, February 29</u> | | |
| 08h00-09h00 | 1 | Breakfast with the Experts: Difficult Cases in Ulcerative Colitis |
| 09h00-10h30 | 1.5 | 2015 Papers that Influenced your Practice |
| 09h00-10h30 | 1.5 | The Future of Hepatology - Diseases and their Cures - Reality or Science Fiction? |
| 11h00-11h40 | 0.75 | Small Group Sessions |
| 11h50-12h30 | 0.75 | Small Group Sessions |
| 13h30-15h00 | 1.5 | Therapeutics in IBD: Past, present and future |

This educational program offers a total of 90.75 hours of Section 1 accredited learning and up to 28.5 credits per delegate
Please visit <http://www.cag-acg.org/> to evaluate the conference and print your certificate



What is Skills Enhancement for Endoscopy® (SEE®)?

- A CAG accredited program delivered by SEE® Certified Faculty at 11 SEE® Certified Centres across Canada. Accredited for either Section One or Section Three credits.

SEE® Train-the-Endoscopy-Trainer (TET) course

Improves teaching skills and procedural conscious competence

SEE® Colonoscopy Skills Improvement (CSI)

Provides up-skilling and improvement of colonoscopy skills

Why SEE® was developed?

- To address the identified gap in the quality of endoscopy skills
- To ensure that the skill levels are standardized across the country

For more information visit www.cag-acg.org/education/see-program or email palma@cag-acg.org



Future CDDW™ Dates

2017

Banff, Alberta
February 26 – March 8

2018

Toronto, Ontario
February 4 – 14

2019

Banff, Alberta
February 24 – March 6

2020






















Montréal, Québec
February 23 – March 4

2021

Banff, Alberta
February 28 – March 10

2016 CAG RESEARCH PROGRAM

IN COLLABORATION WITH THE CIHR AND OUR VALUED RESEARCH PARTNERS

| | | |
|---|---|---|
|  | CCC-CIHR-CAG New Investigator Award (1) (award is for five years) |  |
|  | CCC-CIHR-CAG IBD Fellowships (3) (awards are for two years) |  |
|  | CAG-CIHR Fellowships (2) (awards are for two years) |  |
|  | AbbVie-CIHR-CAG IBD Fellowship (1) (award is for two years) |  |
|  | Allergan-CIHR-CAG Moptility Fellowship (1) (award is for two years) |  |
|  | Takeda-CIHR-CAG Fellowship (1) (award is for two years) |  |
|  | Pentax-CIHR-CAG Endoscopy Fellowship (1) (award is for two years) |  |
|  | Shire-CAG Research Resident Awards (2) | |
|  | Ferring-CAG Research Resident Awards (2) | |
|  | Allergan-CAG Research Resident Award (1) | |
|  | CAG Summer Studentships (12) | |
|  | CCC Summer Studentships (6) | |
|  | CDHF-CAG Ivan Beck Memorial Summer Studentship (1) |  |

The CAG wishes to express its sincere appreciation to the above sponsors
for their support of these Research Programs



CDDW™ SPONSORS

Platinum

AbbVie
Janssen Inc.

Gold

Allergan Canada
Olympus Canada
Takeda Canada, Inc.
Gilead Sciences Canada, Inc.
Merck Canada Inc.
Fairmont Queen Elizabeth

Silver

Pentax Medical
Bristol-Myers Squibb Canada

Bronze

Shire Pharma Canada ULC
Ferring Pharmaceuticals
Lupin Pharma Canada Ltd.